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DHHC5 REGULATES BETA-ADRENERGIC SIGNALING IN THE HEART
THROUGH PALMITOYLATION OF G ALPHA PROTEINS

(Jessica) Jie Chen, B.A.

Advisory Professor: Darren Boehning, Ph.D.

S-palmitoylation is a reversible posttranslational modification that plays an
important role in regulating protein localization, trafficking, and stability. Recent
studies have shown that some proteins undergo extremely rapid
palmitoylation/depalmitoylation cycles after cellular stimulation supporting a direct
signaling role for this posttranslational modification. The work in this dissertation
investigated whether β-adrenergic stimulation led to stimulus-dependent
palmitoylation of downstream signaling proteins in immortalized and primary cell
models. I found that β-adrenergic stimulation led to rapidly increased Gαs and
Gαi palmitoylation only in primary cardiomyocytes. The kinetics of palmitoylation
was temporally consistent with the downstream production of cAMP and
contractile responses. I identified the plasma membrane-localized palmitoyl
acyltransferase DHHC5 as an important mediator of the stimulus-dependent
palmitoylation in cardiomyocytes. Knockdown of DHHC5 showed that this
enzyme is necessary for palmitoylation of Gαs, Gαi, and functional responses
downstream of β-adrenergic stimulation. A palmitoylation assay with purified
components revealed that Gαs and Gαi are direct substrates of DHHC5. Finally,
viii

we provided evidence that the C-terminal tail of DHHC5 can be palmitoylated in
response to stimulation and such modification is important for its dynamic
localization in the plasma membrane. My results reveal that DHHC5 is a central
regulator of signaling downstream of β-adrenergic receptors in cardiomyocytes.
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Chapter I: Introduction

This chapter is partially based upon a review article originally published in

Chen, J. J., & Boehning, D. (2017). Protein lipidation as a regulator of apoptotic
calcium release: Relevance to cancer. Frontiers in oncology, 7, 138.

Lipidations and their enzymatic regulators
Protein lipidation is the cotranslational or posttranslational covalent
addition of a variety of lipids, including fatty acids, isoprenoids and cholesterol, to
target proteins (Table 1). Lipidation can be categorized into two types based on
the location of the modified proteins: those that are modified in the endoplasmic
reticulum (ER) lumen and secreted, and those that are modified in the cytoplasm
or on the cytoplasmic face of membrane [1]. The former type includes
glycosylphosphatidylinositol (GPI) anchor and cholesterylation, and the latter
type includes N-myristoylation, acylation, and prenylation.
GPI anchor was first discovered in the parasite Trypanosoma brucei
where the highly expressed variant surface glycoprotein (VSG) is anchored to the
cell surface via a glycolipid containing phosphatidylinositol [2-4]. Since then,
many proteins in mammals and lower eukaryotes such as protozoa have been
shown to contain GPI anchors with enormous structural variety, most of which
include an ethanolamine attached to the carboxyl terminus of the protein, a

glycan core, inositol, and lipid moieties [5-7]. GPI-anchored peptides often
include a cleavable N-terminal signal sequence, which directs the peptide to the
ER lumen, and a hydrophobic C terminal sequence that is cleaved at the time of
GPI anchor addition [6, 8, 9]. GPI anchors facilitate tethering of proteins to the
extracellular face of the plasma membrane and are important for many cellular
functions, including adhesion, membrane trafficking and immune system
signaling [10-12].
The GPI precursor, formed in the ER lumen, is transferred to target
proteins by GPI transamidase, a membrane-bound multi-subunit enzyme [13-16].
GPI transamidase cleaves the C-terminal signal peptide of the target proteins,
and forms an enzyme-substrate intermediate, allowing the nucleophilic attack by
the terminal amino group of the preformed GPI [17].
Cholesterylation is a characteristic of the mammalian Hedgehog family
proteins, which are secreted signaling proteins that regulate embryonic
patterning of many tissues and structures [18, 19]. The Hedgehog protein
undergoes an autocatalytic processing that internally cleaves between the
conserved Gly257 and Cys258 at the GCF motif, and yields a ~20kD N-terminal
signaling domain and a ~25kD C-terminal catalytic domain [20, 21]. The Nterminal domain receives a cholesterol moiety and is active in signaling [19, 21,
22]. Interestingly, multiple studies have detected other potentially cholesterylated
proteins [19, 23]. However, the identification of these potential cholesterylation
targets remains to be elucidated. Cholesterylation of the N-terminal signaling
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domain of Hedgehog seems to be only dependent on the presence of the Cterminal catalytic domain, suggesting that this process is autocatalytic [19].
N-myristoylation is the attachment of the 14-carbon myristic acid to a Nterminal Gly residue via an amide bond [24]. It was first identified as a blocking
group that prevents Edman degradation on the N-terminus of the catalytic
subunit of cyclic AMP-dependent protein kinase and the calcium-binding βsubunit of calcineurin [25, 26]. Many other proteins regulating key signaling
pathways, including the Src family non-receptor protein tyrosine kinases [27, 28]
and Gα proteins [29, 30] were shown to be myristoylated. These proteins contain
the N-terminal sequence Met-Gly- and often have a Ser/Thr/Cys at position 6 [24,
31]. Myristoylation can happen cotranslationally following the removal of the
initiator methionine residue [32]. Although myristoylation is required for
membrane targeting of many proteins, it is not sufficient for stable membrane
anchoring due to its weak hydrophobic nature and often needs subsequent lipid
modifications [33-35]. Additionally, myristoylation can also happen
posttranslationally during apoptosis following the caspase cleavage of substrate
proteins that exposes an internal glycine [36-39]. Many apoptotic proteins,
including Bid, gelsolin and p21-activated kinase 2, require posttranslational
myristoylation following caspase cleavage for proper subcellular localization and
subsequent functions [36-38].
N-myristoylation is catalyzed by N-myristoyltransferases (NMTs) [40-42].
NMTs bind first to myristoyl-CoA and then to the peptide, followed by a direct
nucleophilic addition-elimination reaction and subsequent release of CoA and the
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myristoylated peptide [43]. Studies in various tissues and cell types have shown
that the enzymatic activity of NMTs is predominantly distributed in the cytosolic
fraction [44-47]. Some studies have shown that low levels of myristoyl-CoA may
be rate limiting for NMT activity [48, 49]. However, the transcriptional upregulation of NMTs under pathological conditions suggests that this might not
always be the case [50].
Acylation is the addition of various fatty acids, such as palmitic acid, oleic
acid and stearic acid, on different amino acid residues [51-53]. One of the beststudied types of acylation is S-palmitoylation, which is characterized by the
reversible addition of the 16-carbon saturated palmitic acid to Cys residues via
labile thioester bonds [53, 54]. Despite the presence of multiple algorithms to
predict palmitoylation sites, there is no validated consensus sequence for
palmitoylation [55-57]. One key aspect of palmitoylation is that its reversibility
allows for a palmitoylation and depalmitoylation cycle that regulates the
posttranslational trafficking and functions of target proteins, such as H- and NRas [58]. Palmitoylation can also occur on large transmembrane proteins,
including ion channels and G protein coupled receptors [59-63]. The roles of
transmembrane protein palmitoylation include regulation of channel
maturation/quality control and association with lipid rafts [64-67].
Protein S-acylation is regulated by palmitoyl acyltransferases (PATs) and
acyl-protein thioesterases, which add and remove the lipid group, respectively.
There are 23 PATs in mammals, all of which share a common DHHC (Asp-HisHis-Cys) motif within a cysteine rich domain [68, 69]. PATs are polytopic
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membrane proteins that are localized to distinct subcellular compartments,
primarily the Golgi apparatus and the plasma membrane [70]. Some DHHC
enzymes show preference for certain types of proteins (i.e. transmembrane
proteins), and in some cases the same substrates can be palmitoylated by
multiple DHHC enzymes [68, 71-73]. Compared to the large amount of studies
on PATs, thioesterases are relatively poorly characterized. Two protein palmitoyl
thioesterases (PPT1/2) and two acyl protein thioesterases (APT1/2) have been
identified [74-77]. PPTs predominantly localize to the lysosomal lumen and are
involved in depalmitoylation during protein degradation, whereas APTs have
cytosolic localization and are shown to depalmitoylate and recycle signaling
proteins such as Ras and growth associate protein (GAP-43) from the plasma
membrane back to Golgi [75-78]. Very recently, two independent groups found
that the α/β-hydrolase domain (ABHD) family of serine hydrolases are potent
depalmitoylating enzymes for select substrates, including PSD-95 and N-Ras
[79, 80].
Prenylation is the addition of the 15-carbon farnesyl or the 20-carbon
geranylgeranyl isoprenoid lipid on cysteine residues via stable thioether bonds
[81, 82]. It requires a C-terminal CAAX motif, where C is a cysteine, A is aliphatic
amino acids and X can be any amino acid. Prenylation at the CAAX motif is
found in many proteins, including mammalian Ras proteins [83, 84]. In addition to
its role in membrane association, prenylation can also regulate protein-protein
interactions and subcellular distribution of the modified targets [85, 86].
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Prenylation is catalyzed by the enzymes farnesyltransferase (FTase),
geranylgeranyltransferase I (GGTase 1), and Rab geranylgeranyltransferase
(GGTase 2) [87-89]. The prenylating enzymes localize to the cytosol and
conjugate isoprenoids generated from the mevalonate/HMG-CoA reductase
pathway to target proteins. Specifically, the isoprenoids farnesyl and
geranylgeranyl are transferred to a C-terminal CAAX motif on target proteins.
Unlike FTase and GGTase 1, geranylgeranyl transfer by GGTase 2 requires the
co-factor REP (Rab escort protein) [90]. GGTase 1 and FTase generally have
high specificity for the protein targets, depending on the X residue [91-93].
However, they can act on each other’s substrates. One example is that K-Ras
and N-Ras, usually targets of FTase, can be geranylgeranylated in Ras-mutant
human cancer cells treated with FTase inhibitors [94, 95]. Removal of the –AAX
tripeptide and methylation of the prenyl-cysteine, catalyzed by the ER membrane
proteins RCE1 and ICMT, respectively, are two post-prenylation steps required
for maturation of prenylated proteins [96-98].

6

Lipid Structure
GPI anchor

Effects on proteins

Enzymatic regulators

Plasma membrane
GPI transamidase
tethering,
Incorporation into specific
membrane domains,
Protein-protein interaction

Cholesterylation
Hedgehog signaling
activation

Autocatalytic

Membrane localization,
Autoinhibition

N-myristoyltransferases

Palmitoylation

Plasma membrane
localization,
Partitioning into lipid rafts,
Protein maturation/quality
control

Palmitoyl
acyltransferases,
Acyl protein
thioesterases,
α/β-hydrolase fold
family proteins

Farnesylation

Farnesyltransferase
Membrane localization
Conformational change
Protein-protein interaction

Myristoylation

Geranylgeranylation

Geranylgeranyl
Membrane localization
Protein-protein interaction -transferase

Table 1. Summary of Different Types of Lipidation.
The lipid moiety structures, effects on target proteins, and enzymatic regulators
of various lipidation. This table is from Chen, J. J., & Boehning, D. (2017). Protein
lipidation as a regulator of apoptotic calcium release: Relevance to
cancer. Frontiers in oncology, 7, 138. Copyrights remain with the authors.
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Palmitoylation and signaling transduction
S-Acylation, more commonly known as S-palmitoylation, is the only
reversible lipidation and therefore its roles in signaling transduction have been
studied extensively. Recent advances in detecting lipidated proteins by proteomic
and targeted approaches have revealed that lipidation of signaling proteins is
essential for regulating a wide variety of signaling pathways.
One of the earliest studies reporting S-palmitoylation in mammalian cells
relies on the incorporation of radiolabeled fatty acid [3H]palmitate into live cells,
followed by fluorography with long exposure (multiple days) [99]. To detect
palmitoylation of specific proteins of interest, either purified proteins are needed
for cell-free labeling with [3H]palmitate, or exposing cells to [3H]palmitate for
extended period of time is needed [100-102]. While these methods have been
used to identify various palmitoylation targets, they have many drawbacks. Other
than the potential health hazard and the time-consuming autoradiograph
exposure step, the sensitivity and the efficiency of radiolabeling are extremely
low for some proteins [103].
Click chemistry based chemical probes are developed as an alternative to
better detect protein palmitoylation (Figure 1A) [104]. Synthetic fatty acid
analogues with alkyne groups at the terminal end furthest away from the carboxyl
group (ω-position) are incorporated into live cells [105]. Cells are then fixed (for
fluorescence imaging) or lysed (for biochemical assays), followed by a copper(I)catalyzed reaction with azide-conjugated fluorescent groups or biotin for
detection [106]. Notably, synthetic fatty acids with different chain lengths are
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shown to incorporate onto proteins via thioester linkage with different efficiency,
suggesting that while palmitoylation is the most commonly studied S-acylation,
other lipid groups can be added [104]. Click chemistry based probes are
especially useful in studies that distinguish the selectivity of different fatty acid
groups [107].
While click chemistry has led to many important discoveries in protein
palmitoylation (reviewed in [108]), the efficiency of incorporating alkyne
conjugated probes onto substrates vary, and thus is not suitable for unbiased
proteomic studies in native tissues. Recently acyl-biotin exchange (ABE, Figure
1B) has been developed to detect S-acylated proteins in various tissues and
organisms [71, 109, 110]. The first step of ABE is blocking the free cysteine sites
on proteins using the thioreactive compound N-ethylmaleimide (NEM) or methyl
methanethiosulphonate (MMTS). Then the labile thioester bonds at the
palmitoylated cysteines are cleaved using hydroxylamine (HA, neutral PH),
exposing the free thiol groups that can be subsequently biotinylated. After
biotinylation, proteins are pulled down using streptavidin beads and eluted.
Standard Western blotting can be used to detect the palmitoylation levels of
proteins of interest [103], or mass spectrometry can be used for global proteomic
analysis [71].
Acyl-resin-assisted capture (Acyl-RAC, Figure 1B) is a recently developed
approach similar to ABE. Instead of using biotin conjugation and streptavidin pulldown, thioreactive Sepharose resin were used after the HA cleavage step [111].
This method reduces the length of the procedure and is shown to have improved
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sensitivity for detecting some palmitoylated proteins while missing some other
proteins detected by ABE [112].
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Figure 1 Schematics of methods to detect protein palmitoylation.
(A) ω-alkynyl fatty acid is incorporated into live cells, followed by click chemistry
to detect palmitoylation using azide-conjugated fluorophore (green) or
biotin/streptavidin-HRP (yellow). (B) Procedures of using acyl-biotin exchange
(ABE) and acyl-resin-assisted capture (Acyl-RAC) to study the palmitoyl
proteome or proteins of interest.
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Due to the proliferation of targeted and proteomic studies using click
chemistry based probes, ABE, or Acyl-RAC to identify fatty acylated proteins,
protein palmitoylation is shown to play central roles in various signaling pathways
[105]. Our group [113] and others [114-117] have investigated the role of
palmitoylation in regulating death receptor signaling. We found that components
of the T cell receptor (TCR) complex such at Lck, Zap-70, PLC-γ1, and other
TCR components were required for apoptotic calcium release in T cells after
engagement of the Fas receptor with Fas ligand [118]. The Src kinase Lck is
myristoylated and doubly palmitoylated on the N-terminus, and these
modifications regulate its plasma membrane localization and partitioning into lipid
rafts. It is known that the Fas macromolecular complex assembles and signals in
lipid rafts [119], so we asked whether Fas stimulation resulted in rapid
palmitoylation of Lck. Fas stimulation resulted in a rapid increase in de novo
palmitoylation of Lck detectable within minutes of Fas receptor engagement
[113]. Surprisingly, after longer period of stimulation (>10 min) of the Fas
receptor, Lck palmitoylation levels rapidly decreased to even lower than the
levels seen in non-stimulated cells. Importantly, the rapid but transient increase
in palmitoylation of Lck closely matched the activation kinetics of signaling
proteins involved in the initiation of Fas receptor signaling [113]. We therefore
proposed that the enzymatic mechanisms controlling stimulus-dependent protein
palmitoylation and depalmitoylation likely are directly activated by components of
the Fas signaling pathway. In the case of Fas signaling, the plasma membrane
localized DHHC21 protein is essential [113]. Presumably Fas stimulation rapidly

12

activates DHHC21 and a yet unidentified acyl-protein thioesterase to regulate
Lck lipidation levels. How the activation of these enzymes occurs is unknown, but
could possibly be regulated either directly or indirectly by calcium ions (Ca2+).
In order to better understand the role of stimulus-dependent rapid
palmitoylation and their roles in signaling transduction, it is worthwhile to consider
the kinetics of the enzymatic machinery. Over 15 years ago it was shown that βAR stimulation resulted in rapid turnover of the palmitoylation [120, 121] and
depalmitoylation [122] cycle of Gαs. The model was based upon availability of
free Gαs: dissociation from the βγ subunits allowed putative palmitoylating and
depalmitoylating enzymes access to the protein. However, a later study found
that stimulation of beta-adrenergic receptors (β-ARs) in kidney fibroblast-like
COS cells and S49 lymphoma cells did not lead to detectable changes in Gα
protein palmitoylation levels using high performance liquid chromatography
(HPLC) [123]. Since then, other proteins such as PSD-95, eNOS, and Ras have
been shown to have increased turnover of palmitoyl groups in response to
various stimuli, suggesting rapid cycling of lipids in various signaling cascades
[124]. However, further studies on the rapid palmitoylation of endogenous
proteins and their downstream functional roles are still needed, especially in
specific cell types including cardiac cells.

Beta-adrenergic signaling in cardiomyocytes
One of the most well studied pathways in the heart is the β-AR signaling
pathway. Drugs that block the activation of this pathway, termed beta-blockers,
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are among the most commonly used medications for pathological conditions
such as heart failure [125, 126]. Heart failure is the leading cause of death in
many developed countries such as the United States [127]. The hallmarks of
heart failure include reduction in response to sympathetic stimulation and thus
inability to increase cardiac output [128]. One of the key signaling pathways that
regulate these processes in cardiomyocytes is the β-AR signaling pathway.
β-ARs are transmembrane G-protein coupled receptors that transmit
extracellular signals to mediate contractility in the heart. Under conditions where
organs and tissues have increased demand for oxygen delivery, the sympathetic
nervous system is activated and neurotransmitters norepinephrine and
epinephrine are produced [129]. When ligands such as norepinephrine and
epinephrine bind to the β-ARs, they interact with distinct classes of the
heterotrimeric G-proteins, consisting of α, β, and γ subunits, and allow for the
exchange of GDP for GTP [130, 131]. Active Gα and Gβγ subunits then
dissociate and trigger different downstream signaling events.
There are two major sub-types of β-ARs in mammalian hearts—β1-AR and
β2-AR. β1-AR is the predominant type and accounts for 75-80% of cardiac β-ARs,
whereas β2-AR accounts for 20-25% [132]. Different subtypes of β-ARs can
couple with distinct subfamilies of G-proteins (Figure 2A). Both β1-AR and β2-AR
associate with Gαs, which results in activation of downstream adenylyl cyclase
(AC) and production of cAMP. The primary target of cAMP is protein kinase A
(PKA), which phosphorylates substrates such as L-type calcium channel (LTCC),
phospholamban (PLB), ryanodine receptor (RyR), and cardiac troponin I (cTnI)
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[133]. PKA-mediated phosphorylation of the plasma membrane localized LTCC
leads to increased Ca2+ uptake into the cell [134]; Phosphorylation of PLB
reduces its inhibitory effects on sarcoplasmic reticulum calcium ATPase
(SERCA), which results in increased Ca2+ storage in the sarcoplasmic reticulum
(SR); RyR phosphorylation leads to increased Ca2+ release from the SR [135];
and cTnI phosphorylation leads to altered Ca2+ affinity for the myofilaments and
cross-bridge kinetics [136]. All of these events result in increased contractility of
cardiomyocytes, also known as positive inotropy. Positive inotropic effect is
defined by an increase in muscular contractile forces [137]. The force production
in cardiomyocytes is dependent on the actin-myosin cross-bridge, which is
regulated by intracellular Ca2+ levels [138]. The majority of the Ca2+ needed for
cardiac contraction is released from the SR through a process called calciuminduced calcium release [139]. Depolarization of the membrane results in the
opening of LTCC and a small amount of Ca2+ influx, which leads to the opening
of RyR and large amount of Ca2+ release from the SR (reviewed in [140]).
Therefore, positive inotropic effects induced by activation of the β-AR signaling
pathway result in increased intracellular Ca2+ levels.
In addition to Gαs, β2-ARs also bind to Gαi, which inhibits the AC-cAMPPKA pathway [141]. Given the relative low numbers of Gαi-coupled receptors
compared to Gαs-coupled receptors under normal physiological conditions, the
overall effect of stimulation by agonists such as isoproterenol (ISO, agonist for
both β1AR and β2AR) leads to positive inotropic effects [142]. However, β2-ARs
shift from Gαs coupling to Gαi coupling when phosphorylated by PKA after
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prolonged stimulation, contributing to desensitization of the pathway [143, 144].
Studies in multiple heart failure models observed increased expression and
receptor coupling of Gαi [145-147]. Additionally, β2-AR stimulation can also
activate the mitogen-activated protein kinase (MAPK) and the
phosphatidylinositol-3’-kinase (PI3K) pathways in a Gαi-dependent fashion and
has protective effect in cardiomyocytes against apoptosis [148]. Spatial and
temporal regulations of signaling proteins are important to mediate subtypespecific responses to β-AR stimulations. In cardiomyocytes, β2-AR, ACs and
certain PKA subunits are enriched in caveolae, lipid-raft-like structures that form
invaginations [149]. Caveolae exist in many tissues and their structure is
dependent on the scaffolding protein caveolin [150, 151]. There are three
members in the human caveolin gene family and caveolin-3 is specific to muscle
cell types [152, 153]. Domain mapping studies identified caveolin-binding motifs
that are present on various signaling proteins downstream of β-ARs, including
Gα proteins [154, 155]. Caveolae provide the spatial proximity of these upstream
proteins in the β-AR signaling cascade that favors the efficient and rapid
recruitment of effectors following receptor activation [149]. Recently, proteomic
studies revealed that palmitoylated proteins are enriched in caveolae, suggesting
that palmitoylation is a better predictor of caveolae localization than caveolin
binding motifs in cardiomyocytes [32]. Therefore, studying stimulus-dependent
palmitoylation of endogenous proteins is crucial for understanding β-AR signaling
in cardiomyocytes.
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Another key aspect of β-AR signaling in the heart is its negative feedback
via receptor desensitization, which is mediated by the serine/threonine kinases
G-protein coupled receptor kinases (GRKs, Figure 2B). GRK2 and GRK5 are the
most abundantly expressed GRK family members in the heart [156, 157]. Both
GRK2 and GRK5 are crucial players in cardiac pathology. In failing heart,
increased expression of GRK2 and GRK5 contribute to decreased β-AR
signaling efficiency and thus disable the contractile function of the heart to meet
its demand [158, 159]. GRKs phosphorylate the ligand-bound receptors, leading
to recruitment of β-arrestin and internalization of the receptor [160]. Plasma
membrane localization of GRKs is crucial for receptor desensitization.
Interestingly, GRK2 is known to go through isoprenylation, a non-reversible lipid
modification at the C-terminal CAAX domain, but isoprenylation alone is not
sufficient for its plasma membrane targeting [161]. Multiple studies have
demonstrated that GRK2 directly binds the dissociated Gβγ subunits, and the
formation of the complex is important for its plasma membrane localization and
functions [162, 163]. Further studies deciphering whether GRK proteins are
subject to other forms of lipidation in cardiomyocytes are necessary.
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Figure 2 Beta-adrenergic signaling pathways in cardiomyocytes
(A) Agonist stimulation of beta-adrenergic receptors (β-ARs) leads to activation
of adenylyl cyclase (AC) and production of cAMP. Protein Kinase A (PKA) is
subsequently activated and phosphorylates L-type calcium channel (LTCC),
phospholamban (PLB), ryanodine receptor (RyR), and cardiac troponin I (cTnI).
Lipid subdomain in the plasma membrane is shown in grey. (B) G protein
coupled receptor kinase (GRK) phosphorylates β-AR, which results in β-arrestin
binding and receptor internalization.
18

Beta-adrenergic signaling and palmitoylation
Many proteins in the β-AR signaling pathway are palmitoylation targets. In
HEK293 cells overexpressing β1-AR, mutation studies using [3H]palmitate
showed that β1AR is palmitoylated at Cys 392, 393, and 414 [164]. Loss of
palmitoylation at these sites did not affect protein stability or plasma membrane
localization, but only the Cys 414 mutant showed reduced internalization
following stimulation. Interestingly, click-chemistry based pulse-chase labeling
showed stable palmitoylation at position 392/393 and fast turnover rate (15 min)
at position 414, suggesting differential regulation and potentially distinct functions
of palmitoylation at these sites.
β2-AR is one of the first G protein coupled receptors (GPCRs, following
the light-activated GPCR rhodopsin [59]) to be identified as a palmitoylation
target. The first reported palmitoylation site on β2-AR is Cys 341, and mutation at
this site led to reduced downstream cAMP production in the Chinese hamster
fibroblast cell line CHW-1102 [61]. Later studies showed that loss of Cys 341
palmitoylation increased receptor phosphorylation level at Ser 345/346 and
uncoupling from Gαs, a process mediated by PKA [165, 166]. In cardiomyocytes,
palmitoylation of β2-AR at Cys 341 is crucial for its association with
phosphodiesterase (PDE) 4D and subsequent β-arrestin mediated internalization
[167]. Recently, a second palmitoylation site Cys 265 was identified within β2-AR
by using acyl-RAC [168]. Palmitoylation at Cys 265 is evident after 20 min of ISO
stimulation and peaks after 120 min. Additionally, this study by Adachi et al. also
revealed that Golgi-localized DHHC9/14/18 redundantly palmitoylate Cys 265,
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but not Cys 341. Adachi et al. proposed that palmitoylation at Cys 265
contributes to preserving β2-ARs at the plasma membrane after sustained
adrenergic stimulation. However, this study used 2-bromopalmitate (2-BP) and
palmostatin B (PalmB) to inhibit and enhance palmitoylation of β2-ARs,
respectively. These methods are not designed for analyzing the functions of
palmitoylation under physiological conditions. Additionally, 2-BP also inhibit other
enzymes including APT1, which catalyzes depalmitoylation [169], and therefore
cannot be used as a reliable way to inhibit palmitoylation.
Gα subunits, including the s, i, o, z, and q, are all shown to incorporate
[3H]palmitate at cysteines near the N-terminus in COS cells or insect Sf9 cells
[170]. Mutation studies showed that palmitoylation of Gαs, Gαq, and Gαo are
essential for their membrane association [171, 172]. In addition to plasma
membrane localization, Gαi and Gαz palmitoylation alters their interaction with
various regulators of the G protein signaling (RGS) proteins in brain [173].
Mutation studies at Cys 3 reported various effects on downstream signaling
events, including activation of AC [174] and MAPK [175]. As mentioned briefly
before, stimulation of β-ARs in cells lines led to increased turnover of the
palmitoylation/depalmitoylation cycle on Gαs [122]. Interestingly, dynamic
palmitoylation of Gα proteins is not specific to the β-AR signaling pathway. Gαi,
Gαo, and Gαq had increased palmitoylation turnover upon serotonin receptor
activation in brain [176].
Additionally, GRK proteins are also shown to be palmitoylation targets.
There are six members in the human GRK gene family [177]. In kidney fibroblast
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COS-7 cell line, GRK6 was shown to be palmitoylated at three cysteines (561,
562, and 565) in the C-terminal domain and the palmitoylation targets the protein
to membrane [178]. Subsequently, all of the four GRK4 isoforms were shown to
be palmitoylated [179]. Mutation studies in COS cells showed that loss of GRK6
palmitoylation did not affect its kinase activity, but greatly reduced its ability to
sequester β2AR following stimulation [180].
GRK2 and GRK5 are the most abundantly expressed GRK family
members in the heart [156, 157]. However, neither of them was shown to
incorporate [3H]palmitate [178]. It is proposed that the basic amino acids at
position 552-562 near the C-terminal domain of GRK5 are important for its
association with the membrane [181]. The positive charges from these basic
amino acids can form electrostatic interaction with the negatively charged lipid
head groups and stabilize GRK5 at the membrane [179, 182]. Multiple studies
have demonstrated that GRK2 directly binds the dissociated Gβγ subunits, which
are isoprenylated, and the formation of the complex is important for its plasma
membrane localization and functions [162, 163]. Given the recent development in
methods to detect endogenous protein palmitoylation levels, we are interested in
identifying the dynamic palmitoylation levels of signaling proteins and their
functional outcomes in cardiomyocytes.

Palmitoyl acyltransferases and their functions in cardiomyocytes
To better understand the role of palmitoylation on signaling transduction in
cardiomyocytes, it is worth considering the enzymatic regulators that catalyze the
21

attachment of palmitic acid moiety onto substrates. As mentioned briefly in
previous sections, 23 DHHC (referring to the conserved amino acids at the
catalytic core) enzymes exist in the human genome [69]. This class of enzymes
was first discovered in yeast for palmitoylation of Ras [183]. In vitro assays using
[3H]palmitoyl-CoA revealed that DHHC enzymes are sufficient for the transfer of
palmitic acid from CoA to target cysteines, and they go through autoacylation,
presumably at the DHHC site [184]. A later study using DHHC2 and DHHC3
showed that DHHC autoacylation at the catalytic Cys site serves as an acylenzyme intermediate in a two-step ping-pong mechanism [185]. Recently, the
crystal structures of zebrafish DHHC15 and human DHHC20 were solved [186].
This study revealed that the binding of Zn2+ ions is crucial for positioning the
catalytic Cys, which is positioned at the protein-lipid interphase, and that the
transmembrane domains form a hydrophobic pocket where acyl-CoA chains of
specific lengths can fit [186]. Despite a highly conserved catalytic domain, the
human DHHC family members display considerable amino acid sequence
divergence, especially in the C-terminal tail region (reviewed in [187]). The roles
of DHHC enzymes and their targets have been extensively studied in the context
of neurological diseases and cancers (reviewed in [188]). However, fewer studies
were dedicated to their functions in cardiac cells.
One of the DHHC enzymes that have been implicated to play a crucial role
in the heart is DHHC16. DHHC16 deficient mice showed severe birth defects
including partial embryonic lethality, eye malformation, and cardiomyopathy
[189]. Zhou et al. identified phospholamban (PLB) as one of the DHHC16
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substrates and palmitoylation of PLB is crucial for obtaining its quaternary
structure. Additionally, Zhou et al. found that introducing PLB deficiency into the
DHHC16 deficiency mice rescued some of the cardiac phenotypes [189]. The
study by Zhou et al. provided the first evidence that DHHC16 is crucial for heart
development. However, many questions remain such as what other substrates
are palmitoylated by DHHC16 in cardiomyocytes? Is there dynamic regulation of
PLB palmitoylation after activation of the β-AR/AC/PKA pathway? One recent
study in the HAP1 cell line reported a palmitoylation cascade in which DHHC16
palmitoylates DHHC6 at three cysteines in the C-terminal SH3 domain [190].
This also raises the question of whether the cardiac phenotypes observed in
DHHC16 mouse model are due to direct effects of DHHC16 or through another
DHHC enzyme.
DHHC5 is one of the best characterized PATs in the heart and
palmitoylation of its substrate phospholemman (PLM) is crucial for mediating a
process called massive endocytosis (MEND). PLM is a regulatory subunit of the
cardiac Na/K pump [191]. PLM can be phosphorylated by PKA and PKC, and
subsequently activates the Na/K pump [192]. On the other hand, PLM can also
be palmitoylated to inhibit Na/K pump activity [193]. Co-immunoprecipitation
experiments showed that DHHC5, along with DHHC 4, 6, and 7, binds PLM. In
adult rat ventricular myocytes (ARVMs), DHHC2, 4, 5, and 7 are most abundantly
expressed at the mRNA level [194]. DHHC5 is one of the few PATs that are
shown to localize at the plasma membrane [70], where its target PLM is located.
Over-expression and knockdown of DHHC5 enhanced and suppressed,
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respectively, PLM palmitoylation levels in cell lines. Additionally, the study by
Howie et al. also identified the PLM palmitoylation site to be at a single Cys in
ARVM [194].
To further elucidate how DHHC5 potentially affects cellular activities in
cardiomyocytes, a DHHC5 knockout mouse model was used to study MEND, a
cellular process that happens during reperfusion of anoxic heart [195] (Figure 3).
MEND is characterized by internalization of more than 70% of the plasma
membrane [196]. MEND can be triggered by the release of Coenzyme A (CoA)
from the mitochondria upon calcium overload and oxidative stress. The presence
of CoA in the cytoplasm allows the synthesis of Acyl-CoA, which can then be
used to palmitoylate surface membrane proteins [196]. Interestingly, MEND can
be promoted by overexpression of palmitoylated PLM [193], providing a potential
mechanism by which DHHC5-mediated palmitoylation of PLM plays an essential
role in mediating MEND. Indeed, myocytes isolated from DHHC5 deficient mice
showed increased Na/K pump activity as well as more surface localized PLM
[197]. Additionally, MEND is inhibited in post-anoxia reperfusion models in the
DHHC5 deficient heart [197]. These data suggest that the availability of Acyl-CoA
can be one potential mechanism by which DHHC5-mediated PLM palmitoylation
is regulated in cardiomyocytes. Interestingly, both PLM and DHHC5 are shown to
be enriched in caveolae [194], suggesting that the physical proximity of the
substrate may be another way to regulate DHHC5-mediated palmitoylation.

24

Figure 3 DHHC5 mediates massive endocytosis in cardiomyocytes
Increased calcium storage in mitochondria or oxidative stress leads to export of
Coenzyme A (CoA) through permeability transition pore (PTP) that spans the
inner and outer mitochondria membranes (IMM and OMM). Palmitoyl-CoA is then
synthesized and used by DHHC5 to palmitoylate phospholemman (PLM) in the
presence of reactive oxygen species (ROS). PLM palmitoylation leads to
massive endocytosis (MEND) and internalization of Na/K pumps.

25

It is worth noting that truncation studies have shown that the C-terminal
domain between N218 and T334 is crucial for DHHC5 substrate recognition
[194]. Additionally, emerging evidence has shown that DHHC5 can be
posttranslationally modified in the C-terminal tail. In neurons, the tyrosine kinase
Fyn phosphorylates DHHC5 at Y533 and forms a DHHC5/Fyn/PSD-95 protein
complex to keep them at the synaptic membrane [198]. Proteomic approaches in
adult mouse forebrain extracts revealed that DHHC5 was found to be
palmitoylated at three potential cysteines in the C-terminus tail (Cys 236, 237,
and 245), some of which are conserved in other DHHC enzymes [199].
Therefore, further studies are needed to identify post-translational modifications
of DHHC5 and how they regulate its activities in cardiomyocytes.
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Chapter II: Material and Methods
This chapter is partially based upon a preprint article:
Chen, J. J., Marsden, A. N., Akimzhanov, A. M., & Boehning, D. (2018)
The palmitoyl acyltransferases DHHC5 mediates beta-adrenergic
signaling in the heart by targeting Gα proteins and G protein-coupled
receptor kinase 2. bioRxiv preprint.

Antibodies, constructs, and reagents
Mouse monoclonal anti-Gαs was purchased from Millipore (MABN543). Rabbit
monoclonal anti-Gαi/o and rabbit polyclonal anti-calnexin was purchased from
Abcam (ab140125, ab22595). Rabbit polyclonal anti-GRK2, anti-PKA C-α, antiPKA RI-α/β were purchased from Cell Signaling (#3982, 4782, 3927). Rabbit
polyclonal anti-AC5/6 was purchased from Millipore (ABS573). Rabbit polyclonal
anti-DHHC5 was purchased from Proteintech (21324-1-AP). Secondary
antibodies conjugated to Alexa-488, Alexa-555 (Molecular Probes), peroxidase
(Jackson ImmunoResaerch), IRDye 680LT, and 800CW (LI-COR) were used.
The 3xFLAG-DHHC5 construct was a gift of Dr. Yusuke Ohno (Sapporo, Japan).
DHHS5 mutant was built using q5 mutagenesis kit (NEB) with primers 5’TGATCATCACAGCCCCTGGGTG-3’ and 5’-AATTCCTCCACACAGTTGTCAC3’. DHHC5 Cys 236 to Cys 245 deletion (DHHC5Δ236-245) mutant was built with
primers 5’-AGTTCTCCAGCACCCAGG-3’ and 5’- GCCATTGGTGAAGGGATTC3’. DHHC5 Cys 236 to Ser (DHHC5C236S) mutant was built with primers 5’27

CACCAATGGCAGCTGTAACAACG-3’ and 5’-AAGGGATTCACACCTCCC-3’.
DHHC5 Cys 245 to Ser (DHHC5C245S) mutant was built with primers 5’CCGTGTCCTCAGCAGTTCTCCAG-3’ and 5’-CTAACGTTGTTACAGCAGCC-3’.
DHHC5C236S_C245S double mutant was built using the same primers as
DHHC5C245S in the DHHC5C236S background. DHHC5 tail-less (DHHC5TL)
mutant was built with primers 5’-ATTTCATGTGTAACTGGTGGCTAGGGGAC-3’
and 5’- CCTGTGAGGCCAGCTACA-3’ so that Val 209 was changed to a stop
codon. DHHC5 truncation mutant that changes Ser 376 to a stop codon
(DHHC5S376STOP) was built with primers 5’CGCCAAGTTGTGACGTGGAGACA-3’ and 5’-CTGGAGGAATGAGGCATG-3’.
DHHC5 truncation mutant that changes Ser 584 to a stop codon
(DHHC5S584STOP) was built with primers 5’CCCCCGTACTTGATCCTCCTCAGATG-3’ and 5’- GCATGGCCTGAGCCTGGT3’. DHHC5 was cloned into the pmCherry-C1 Vector from Clontech (632524)
using the NEBuilder High-Fidelity DNA Assembly Cloning (NEB, E5520) with
primers 5’CGACGGTACCGCGGGCCCGGGATCCATGCCCGCAGAGTCTGGAAAG-3’
and 5’TCAGTTATCTAGATCCGGTGGATCCTCACACCGAAATCTCATAGGTGG-3’
following the manufacturer’s protocol. Isoproterenol was purchased from Tocris
(#1747) and was prepared fresh before use. Silencer Select DHHC5 siRNAs
(s168613, s168614) and negative control medium GC duplex siRNA (12935112)
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were purchased from ThermoFisher Scientific. All other reagents were purchased
at the highest possible purity from Sigma-Aldrich.

Cell culture
The rat myoblast H9c2 and HEK293 cell lines were obtained from the American
Type Culture Collection (ATCC) and maintained according to ATCC guidelines.
Neonatal rat ventricular cardiomyocytes (NRVMs) were prepared from 1 to 2 dayold Sprague-Dawley rat pups, as previously described [200]. Animals were
purchased from Texas Animal Specialties (Humble, TX) and processed on the
same day. Cardiomyocytes were plated on Primaria polystyrene plates (Corning)
or fibronectin-coated glass coverslips. Cells were initially maintained in a mixture
of 40% DMEM, 40% Ham’s F10 culture medium, and 20% FBS. Forty-eight
hours after plating, the media was replaced by a mixture of 50% DMEM and 50%
Ham’s F10 culture medium, supplied with human recombinant insulin (Gibco),
transferrin, and thyroxine (Sigma). Cytosine-B-D-arabino-furanoside
hydrochloride (10µM, Sigma) was present in all culture medium to prevent
proliferation of fibroblasts or endothelial cells. Cardiomyocytes were transfected
with Lipofectamine 3000 following manufacturer’s instruction. All siRNA knockdown experiments were carried out 48 hours following transfection and within
one week of initial plating. The vertebrate animal procedures were approved by
the Animal Welfare Committee (AWC) at UTHealth. For each assay, n represents
number of biological replicates from separate NRVM preps.
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Preparation of adult left ventricular lysates
Frozen left ventricle tissue from adult rats was a gift of Dr. Karmouty-Quintana
(UTHealth) and Drs. Youker and Amione-Guerra (Houston Methodist Hospital).
Frozen tissue was homogenized and lysed in 1% β-D-maltoside in PBS,
supplemented with a protease inhibitor mixture (Roche 11873580001) and the
acyl protein thioesterases inhibitor ML211 (10µM, Cayman Chemicals), followed
by centrifugation (8000 xg, 5min) to remove insoluble material. The cleared
supernatant was stored at -80°C.

Acyl biotin exchange
NRVMs were plated at a density of 1,000 cells per mm2 on 6-well plates. For
control and DHHC5 knockdown experiments, the total amount of siRNA
transfected was 30 pmol per 900,000 cells. NRVMs were stimulated with 10 µM
ISO at room temperature for indicated times, followed by scraping on ice in icecold lysis buffer. Cells were lysed in 1% β-D-maltoside or 0.5% SDS (for DHHC5
tail palmitoylation experiments) in PBS, supplemented with a protease inhibitor
mixture (Roche 11873580001) and acyl protein thioesterases inhibitor ML211 (10
µM, Cayman Chemicals). Acyl biotin exchange was performed as described
previously with slight modifications [71]. Briefly, proteins were precipitated by
choloroform-methanol (CM) and incubated with 10 mM N-ethylmaleimide (NEM)
overnight at 4°C with gentle mixing. Following three rounds of CM precipitation,
samples were incubated with 400 mM hydroxylamine (HA, pH=7, freshly
prepared) and 1 mM HPDP-biotin for 50 min at 37°C with gentle mixing. When a
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minus-HA treated sample was included, the sample was divided into two equal
parts after the third precipitation and sodium chloride was used instead of HA.
After three rounds of CM precipitation, samples were incubated with Streptavidinagarose (Pierce) beads for at least 90 min up to 8 hrs at room temperature with
gentle mixing. Following four rounds of washes, bound proteins were eluted for
15 min at 80°C with shaking in 30 µl of elution buffer containing 1% βmercaptoethanol and 2 mM DTT. The supernatants were transferred to new
tubes and 20 µl of the samples were loaded onto a 4-20% gradient SDS-PAGE
gel (BIO-RAD), followed by transfer to nitrocellulose membrane and
immunoblotting.

cAMP ELISA
For quantification of intracellular cAMP levels, NRVMs were plated at a density of
175 cells per mm2 on 24-well plates. For siRNA knockdown experiments, cells
were transfected with 5 pmol of siRNA for 48 hr. For knockdown and rescue
experiments, cells were transfected with 5 pmol of siRNA for a total of 48 hr and
2 µg of DNA were transfected 24 hr after the siRNA transfection. Cells were
stimulated with 1 µM ISO and assayed using the direct cAMP ELISA kit (Enzo)
per manufacturer’s instructions. Each well was lysed in 250 µl provided lysis
buffer by scraping the wells. Final results were analyzed using a Tecan Spark
Multimode Microplate Reader. Each experiment was performed with at least
three biological replicates.
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Calcium imaging
NRVMs were plated at a density of 300 cells per mm2 on fibronectin-coated glass
coverslips. Cardiomyocytes were loaded with Fura-2 AM as described previously
[200]. Briefly, cardiomyocytes were incubated with Fura-2 AM in imaging solution
(1% BSA, 107mM NaCl, 20 mM HEPES, 2.5 mM MgCl2, 7.5 mMKCl, 11.5mM
glucose, and 1 mM CaCl2) for 30 min at room temperature. Then cardiomyocytes
were incubated in imaging solution without Fura-2 AM for 20 min at room
temperature before mounting onto the microscope. Images were taken on a
Nikon TiS inverted microscope with a 40X oil immersion objective, and images
were taken every second with a Photometrics Evolve EMCCD camera. ISO (10
µM) was added after 2 min of baseline recording. An oscillation was counted
when the Fura-2 ratio rose 10% above the baseline ratio. Oscillation frequencies
before and after ISO were calculated from five coverslips for each condition and
mean ± SEM were plotted as described [200].

TIRF microscopy and analysis
NRVMs were plated at a density of 200-250 cells per mm2 on fibronectin-coated
glass coverslips and transfected with mCherry-DHHC5 or mCherry-DHHC5Δ236245 for 24 hrs using Lipofectamine 3000. Images were taken on a Nikon Eclipse
TiS TIRF microscope with a 60X Apo TIRF oil immersion objective every 500 ms
with an Andor Zyla sCMOS camera. Beating cardiomyocytes were located and
imaged for three minutes before treating with ISO (10 µM). Cells were
continuously imaged for 10 min after stimulation. Images were analyzed using
the TrackMate v3.8.0 Plugin for Fiji [201]. We used the LoG detector for particles,
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and the thresholds were determined for each cell based on the fluorescence
intensity. We used the LAP tracker (max distance 15 pixel, max frame gap 4) for
particle tracking. All output files from TrackMate were used for data analysis.
“Links in track statistics” data from each cell was exported from TrackMate as
comma-separated values (csv) files and analyzed using custom Python scripts
utilizing the pandas and NumPy packages for data analysis. Tracking files from
individual cells were merged together into wildtype and mutant data frames. Time
bins of 30 s were created for the 13-minute experiment duration and each row of
the data frames, representing 0.5 s, were assigned to these time bins.
Downstream analyses were carried out using these 30 s time bins. Particle
lifetime analysis was performed by extracting all particles which existed during a
30 s bin at the start of the experiment (time 0 min) and during one bin at the end
of the experiment (time 10 min). The time that a particle existed (in frames) within
this window was calculated for each particle and the normalized distribution was
plotted along with the kernel-density-estimate (KDE) of the distribution [202].
Plotting was performed in Python using the seaborn and matplotlib packages.
The mean squared displacement of every particle was calculated in Python using
the following formula at each frame (n) (0.5s) for a total of 60 frames (N) where x
and y represent the coordinate position of the particle as determined by
TrackMate:
1
𝑀𝑆𝐷 𝑛 =
𝑁−𝑛
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The MSD at each frame was plotted for a 30 s bin immediately prior to treatment
(frames 300-360) and for a 30 s window 10 minutes post-treatment (frames
1560-1620).

Immunofluorescence staining
NRVMs were plated at a density of 250 cells per mm2 on fibronectin-coated glass
coverslips. Immunofluorescence staining was performed as described previously
[200]. Briefly, H9c2 or NRVMs were fixed using 100% ice-cold methanol at -20°C
for 20 min, and permeabilized using 0.1% saponin in PBS at room temperature
for 10 min. After washing with PBS, samples were blocked in 5% FBS and 1%
BSA in PBS. Primary antibodies were diluted in the same buffer as blocking.
Anti-DHHC5 was used at a concentration of 1:100. Secondary antibodies were
used at a concentration of 1:500. Samples were mounted in VECTASHIELD
antifade mounting medium with DAPI, sealed, and kept at 4°C. Images were
taken on a ZEISS Cell Observer SD laser scanning confocal system with a 63x
oil objective. For the quantification of plasma membrane localization of DHHC5,
the percentage of cells displaying near plasma membrane localization (example
shown in Figure 7) from five separate fields was scored in a blinded manner.

In vitro DHHC5 activity assay
HEK293T cells were not transfected (control) or transfected with FLAG- or
mCherry- tagged DHHS5 and DHHC5 using Lipofectamine 3000 for 18-24 hrs.
Cells were lysed in lysis buffer containing 0.5% SDS, 150mM NaCl, 50mM Tris,
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1% Triton and 1mM EDTA, in the presence of protease inhibitor (Roche). Lysates
are incubated at 4°C with rotation for 15 min, sonicated until no longer viscous,
and diluted using lysis buffer to a final concentration of 0.01% SDS. Rabbit
monoclonal anti-FLAG (CST147935) or RFP-Trap (ChromoTek) were used to
immunoprecipitate DHHS/C5. The reaction mix contains 500 nM recombinant
human Gαs (Origene TP314318), non-myristoylated rat Gαi proteins (Gift of Dr.
Carmen Dessauer and Dr. Tanya Baldwin) or recombinant human GAPDH
(abcam ab77109), 200 nM DTT, 300 µM DDM, and 5 µM palmitoyl CoA{N-[(7nitro-2-1,3- benzoxadiazol-4-yl)-methyl]amino} (Avanti lipids). For samples mixed
with hydroxylamine (HA), final concentration of 400 mM neutral HA is present in
the reaction mix. Reactions were started by adding palm-CoA-NBD and kept
shaking at 37°C. At the indicated time points, a portion of the reaction was taken
out and stopped by adding lysis buffer and heating at 80°C for 15 min. Beads
were boiled in the presence of 2% BME to check for DHHS/C5 proteins at the
end of the reactions. All samples were run on 4-20% gradient gels, transferred,
and imaged using a ChemiDoc XRS+ system (BIO-RAD) with a Blue Epi
illumination and a 530/25 filter for the NBD signals. Standard Western Blotting
was used to check for the level of total substrate proteins.

Acyl-PEG-Exchange
H9c2 cells were lysed in 1% β-D-maltoside in PBS, supplemented with a
protease inhibitor mixture and APT inhibitor ML211 (10 µM). Acyl polyethylene
glycol (PEG) exchange was performed as described previously with slight
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modifications [203]. Briefly, proteins were precipitated by chloroform-methanol
(CM) and incubated with 0.2% MMTS at 42°C for 15 min. Following four rounds
of CM precipitation, protein pellet was dissolved in buffer containing 2% SDS,
5mM EDTA, 100mM HEPES, PH 7.4 (refer to as 2SB). Samples were divided
into two equal parts, and one part was incubated with 2M Hydroxylamine (HA,
PH=7) while the other part with 2M NaCl (-HA, negative control) for 1 hr at room
temperature with end-to-end rotation. Samples were washed with three rounds of
CM precipitation and dissolved in 2SB. Equal volume of 2mM PEG maleimide
(mPEG) was added to samples and incubated at room temperature for 2 hr with
gentle mixing. Excess mPEG was removed using three rounds of CM
precipitation and the protein pellet was dissolved in 2SB. Loading buffer
containing 2% BME and 2mM DTT were added to the samples and heated at
80°C for 15 min. Samples were ran on 4-20% gradient gels, followed by standard
western blotting.
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Chapter III: DHHC5 Mediates Beta-adrenergic Signaling Though
Palmitoylation of G Alpha Proteins in Cardiomyocytes

This chapter is partially based upon a preprint article:
Chen, J. J., Marsden, A. N., Akimzhanov, A. M., & Boehning, D. (2018)
The palmitoyl acyltransferases DHHC5 mediates beta-adrenergic
signaling in the heart by targeting Gα proteins and G protein-coupled
receptor kinase 2. bioRxiv preprint.

Introduction
Beta-adrenergic receptor (β-AR) signaling is one of the central regulators
of contractile function in the heart. Like other G protein-coupled receptors
(GPCRs), β-ARs associate with heterotrimeric G proteins, composed of α, β, and
γ subunits [204, 205]. Upon activation, β-ARs act as guanine nucleotide
exchange factors and replace the GDP with GTP in the G protein α subunits
[206]. Cardiac β-ARs associate with both Gαs and Gαi, which can stimulate or
inhibit adenylyl cyclase, respectively [207, 208]. Adenylyl cyclase produces the
secondary messenger cAMP, which activates multiple downstream effectors,
including protein kinase A (PKA) [209, 210]. PKA phosphorylates many
substrates that alter contractile functions, including ryanodine receptors,
phospholamban, and cardiac troponin I [211-213]. Given the crucial roles of β-AR
signaling in regulating cardiac function, it is not surprising that this pathway is
tightly controlled.
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Multiple members of the β-AR signaling pathway undergo protein
palmitoylation, a posttranslational modification that adds a 16-carbon palmitic
acid to cysteine residues via a labile thioester bond. Protein palmitoylation is
catalyzed by a class of enzymes termed palmitoyl acyltransferases (PATs).
There are at least 23 mammalian PATs that share a conserved Asp-His-His-Cys
(DHHC) domain that is essential for PAT activity [68]. Most of the DHHC PATs
are localized to the Golgi apparatus and play crucial roles in the cycling of
palmitoylated substrates between the Golgi apparatus and the plasma
membrane. Recently our lab showed that the plasma membrane-localized
DHHC21 is responsible for rapid, agonist-induced palmitoylation of substrates
downstream of the Fas death receptor in T-cells [113].
Small G proteins such as Gα are classic palmitoylated proteins, and this
modification is crucial for their plasma membrane targeting and subsequent
functions [170, 171]. Studies in HeLa cells and primary hippocampal neurons
suggested that Gα proteins can be palmitoylated by Golgi-localized DHHC3 and 7 [214]. The enzymatic activity regulating Gα protein palmitoylation in cardiac
tissue is incompletely understood. Recently, the β2-AR was reported to be
palmitoylated at two cysteine residues in cardiomyocytes in a PKA-dependent
manner resulting in internalization after 20 minutes of isoproterenol (ISO)
stimulation [168]. In this study it was found that the Golgi-associated DHHC9, 14,
and 18 may mediate β2-AR palmitoylation. In order for palmitoylation to regulate
GPCR signaling with kinetics consistent with a signaling role, presumably a
plasma membrane localized DHHC enzyme should be activated. In
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cardiomyocytes, the plasma membrane localized DHHC5 enzyme has been
shown to be concentrated in caveolae and regulate the dynamic palmitoylation of
phospholemman, a regulatory subunit of the Na pump [193, 194]. Importantly,
phospholemman palmitoylation is dependent upon PKA phosphorylation,
indicating it is likely palmitoylated in a stimulus-dependent manner [193].
Whether DHHC5 regulates the dynamic palmitoylation of other substrates after βAR stimulation in cardiomyocytes is not known.
Here I show that Gαs and Gαi are palmitoylated within minutes of β-AR
activation in ventricular cardiomyocytes. The palmitoylation kinetics are
temporally consistent with the downstream cAMP production and changes in
contractility. Knockdown of DHHC5 significantly inhibits agonist-induced
palmitoylation and downstream responses indicating that this enzyme is required
for β-AR signaling in cardiomyocytes. Additionally, I show that Gαs and Gαi are
direct substrates of DHHC5 in vitro. These results uncover a novel and essential
palmitoylation-dependent signaling cascade downstream of β-ARs in
cardiomyocytes.

Results
Acyl-biotin exchange reveals known and novel palmitoylation proteins in
the cardiac β-AR signaling pathway
Multiple methods have been developed to detect protein palmitoylation.
The traditional method of metabolically labeling target proteins with [3H]-palmitate
is powerful, but not ideal for unbiased identification of multiple palmitoylation
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substrates. The efficiency of labeling is dependent on the ability of cells to
incorporate labeled palmitate and the palmitate turnover rate of each individual
protein [103]. In addition, exogenous addition of palmitic acid to cells may drive
non-physiological processes including altering the acylation state of signaling
proteins. More recently, acyl-biotin exchange (ABE, Figure 1B in Chapter I) has
been exploited as an efficient way of detecting the endogenous palmitoyl
proteome in various tissues and organisms [71, 109, 110]. The first step of ABE
is blocking the free cysteine sites on proteins in cell lysates by using the
thioreactive compound N-ethylmaleimide (NEM). Subsequently the labile
thioester bond at the palmitoylation site is cleaved using neutral hydroxylamine
(HA), exposing the free thiol group that can be subsequently biotinylated. After
biotinylation, proteins are pulled down using streptavidin beads and eluted,
followed by Western blotting to detect palmitoylated proteins. I used multiple rat
cardiac cell types, including the myoblast cell line H9c2, neonatal rat ventricular
myocytes (NRVM), and adult murine left ventricular tissue for detection of
palmitoylated proteins downstream of β-AR (Figure 4A-C). I used calnexin as a
positive control for protein palmitoylation in all experiments [215, 216]. As
expected, I found that Gαs and Gαi are palmitoylated in both cell types and in
cardiac tissue. Additionally, I also identified G protein-coupled receptor kinase 2
(GRK2), a negative regulator of β-AR signaling, as a novel palmitoylation target
in H9c2 cells. Though GRK2 has never been shown as a palmitoylated protein,
another member of the GRK family, GRK6, has been shown to be palmitoylated
at the carboxyl-terminal domain in COS-7 cells [178]. The PKA regulatory
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subunit showed low levels of palmitoylation in H9c2 cells consistent with a
previous proteomic study [217]. However, I cannot conclude that PKA regulatory
subunit is indeed palmitoylated in H9c2 cells because the signal was only
marginally stronger than the background signal in the -HA lane. Other methods,
for example acyl-RAC, may be more suitable for confirming the palmitoylation
state of PKA regulatory subunits. No palmitoylation was detected for other
proteins downstream of β-ARs, including adenylyl cyclase 5/6 or PKA catalytic
subunits (Figure 4A-C). Consistent with our ABE results in adult rat ventricular
tissue (Figure 4C), a palmitoyl proteomic study in adult rat ventricular
cardiomyocytes found that Gαs and Gαi are palmitoylated proteins [218].
Interestingly, Wypijewski et al. identified adenylyl cyclase 6, but not any other
proteins listed in my study, as a potential palmitoylated protein.
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Figure 4 Palmitoylation of cardiac proteins as determined by acyl-biotin
exchange (ABE)
ABE was performed on H9c2 cells (A), neonatal rat ventricular myocytes
(NRVMs, B), and adult rat left ventricular (LV) tissue (C). Calnexin was used as a
positive control. The absence of hydroxylamine (-HA) was used as a negative
control for non-specific binding to the streptavidin beads. Abbreviations are as
follows: GRK2, G protein-coupled receptor kinase 2; AC, adenylyl cyclase; PKA
R, protein kinase A regulatory subunit; PKA C, PKA catalytic subunit.
Overexposure of the PKA R blot is indicated as a (+). This figure is modified from
Chen, J. J., Marsden, A. N., Akimzhanov, A. M., & Boehning, D. (2018) The
palmitoyl acyltransferases DHHC5 mediates beta-adrenergic signaling in the
heart by targeting Gα proteins and G protein-coupled receptor kinase 2. bioRxiv
preprint. Copyrights for this article remain with the authors.
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Activation of β-ARs induces rapid protein palmitoylation in cardiomyocytes
Previous studies indicate that stimulation of β-ARs increases the rate of
turnover of palmitate groups on Gα [122, 171, 219]. To examine whether Gαs
and Gαi proteins are palmitoylated upon β-AR activation in cardiomyocytes, I
stimulated primary NRVMs with the β-AR agonist isoproterenol (ISO) and
collected lysates from 0 to 30 minutes. I then performed ABE to quantify
palmitoylation levels of proteins of interest. I found that both Gαs and Gαi had
significantly increased palmitoylation levels within a minute of ISO stimulation
(Figure 5A,B). Calnexin is a well-characterized and stably palmitoylated protein
[215]. I found that palmitoylation levels of calnexin were marginally elevated after
ISO stimulation. It is known that calnexin is localized to the ER [220], a separate
membrane system from the plasma membrane where many of the β-AR
signaling proteins are localized. Therefore, due to the modest increases in
calnexin palmitoylation levels and localization to a separate membrane system, I
used calnexin to normalize the changes in palmitoylation levels of Gα proteins
(Figure 5B). By 30 min the palmitoylation levels of Gαs and Gαi were
significantly reduced suggesting a temporally distinct activation of acyl protein
thioesterases. Interestingly, I also found that GRK2 can be palmitoylated after
ISO stimulation (Figure 6). The kinetics of GRK2 palmitoylation were
characterized by increased levels at later time points compared to Gα proteins
and were maintained throughout the 30 min time course (Figure 6B). These
delayed kinetics may be functionally relevant to the negative regulatory role of
GRK2 in the β-AR pathway. I next examined whether the agonist-induced

43

palmitoylation is temporally consistent to downstream events mediating
contractile functions. To test whether the kinetics of Gα palmitoylation correspond
to downstream cAMP production, I measured intracellular cAMP levels in NRVMs
after ISO stimulation. We found that cAMP levels increased within a minute of
ISO stimulation and then decreased within 30 min (Figure 5C), which was
temporally consistent with the kinetics of Gα palmitoylation (Figure 5A,B). ISO is
known to induce positive inotropy in NRVMs [221]. I used Fura-2 AM, a
ratiometric calcium indicator, to monitor the intracellular calcium levels in
spontaneously beating NRVMs. I observed an increase in calcium oscillation
frequency (corresponding to beating frequency) within a minute of ISO
stimulation, which like cAMP production, was temporally consistent with the
kinetics of Gα palmitoylation (Figure 5D). These results suggest that rapid
palmitoylation of signaling proteins after β-AR stimulation may play a role in the
assembly of the macromolecular β-AR signaling complex and efficient
downstream modulation of cardiomyocyte contractility. To directly address this
possibility, I targeted the enzymatic machinery potentially responsible for rapid
palmitoylation of signaling proteins in cardiomyocytes.
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Figure 5 Isoproterenol induces rapid and reversible palmitoylation of Gαs
and Gαi in cardiomyocytes
(A) Neonatal rat ventricular myocytes (NRVMs) were treated with 10 µM
isoproterenol (ISO) for the indicated times. ABE was used to detect
palmitoylation levels. Calnexin, which has a relatively slow turnover of
palmitoylation groups, was used to normalize turnover rates assessed by ABE.
(B) Fold changes of palmitoylation levels of Gαs and Gαi normalized to calnexin
at the indicated time points compared to 0 min (n=3). (C) NRVMs were treated
with 10 µM ISO for indicated time points and intracellular cAMP concentration
was measured using ELISA (n=5). (D) Representative single cell trace of the
Fura-2 ratio in a NRVM cell treated with 10 µM ISO at the indicated time point.
*p<0.05 (paired t test). This figure is modified from Chen, J. J., Marsden, A. N.,
Akimzhanov, A. M., & Boehning, D. (2018) The palmitoyl acyltransferases
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DHHC5 mediates beta-adrenergic signaling in the heart by targeting Gα proteins
and G protein-coupled receptor kinase 2. bioRxiv preprint. Copyrights for this
article remain with the authors.
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Figure 6 Isoproterenol induces rapid palmitoylation of GRK2 in primary
cardiomyocytes
(A) Neonatal rat ventricular myocytes (NRVMs) are treated with 10 µM
isoproterenol (ISO) for the indicated times. ABE was used to detect
palmitoylation levels of GRK2 in response to ISO stimulation. This blot was
generated from the same ABE reaction as shown in Figure 5. (B) Quantification
of palmitoylation levels normalized to calnexin at the indicated time points.
*p<0.05 (paired t test, compared to time 0). This figure is modified from Chen, J.
J., Marsden, A. N., Akimzhanov, A. M., & Boehning, D. (2018) The palmitoyl
acyltransferases DHHC5 mediates beta-adrenergic signaling in the heart by
targeting Gα proteins and G protein-coupled receptor kinase 2. bioRxiv preprint.
Copyrights for this article remain with the authors.
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The palmitoyl acyltransferase DHHC5 mediates β-AR signaling in
cardiomyocytes
I have previously shown that the plasma membrane-localized DHHC
enzyme DHHC21 is responsible for rapid agonist-induced palmitoylation of
components of the Fas receptor pathway in T cells [113]. Therefore, I
hypothesized that the DHHC enzyme that catalyzes the ISO-induced
palmitoylation in cardiomyocytes must similarly be localized to the plasma
membrane. In addition to DHHC21, DHHC5 is one of the few DHHC enzymes
that has been shown to be at least partially plasma membrane localized [70]. At
the transcript level, DHHC5 is abundantly expressed in rat cardiomyocytes [194].
I analyzed the localization of endogenous DHHC5 in NRVMs.
Immunofluorescence staining showed that DHHC5 has Golgi/ER and plasma
membrane localization (Figure 7A). To determine whether DHHC5 is responsible
for ISO-induced palmitoylation in NRVMs, I used siRNA to knockdown DHHC5
(Figure 7B,C). I also confirmed that siRNA knockdown of DHHC5 did not affect
the total proteins level of Calnexin, Gαs, or Gαi (Figure 7D,E). I then performed
ABE and found that agonist-induced palmitoylation of Gαs and Gαi is
undetectable in DHHC5 knockdown cells (Figure 8A-B). Next I determined
whether DHHC5 activity is required for signaling downstream of ISO stimulation
in NRVMs. I found that DHHC5 knockdown cells have diminished levels of cAMP
production following ISO stimulation (Figure 8C). Additionally, I found that
DHHC5 knockdown cells no longer have an increased calcium oscillation
frequency in response to ISO stimulation (Figure 8D). These data indicate that
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DHHC5 is essential for signaling through the β-AR pathway in cardiomyocytes,
and this is likely mediated at least in part by regulating the palmitoylation state of
Gα proteins. To address whether my observation in cardiomyocytes are due to
Gαs and Gαi being direct substrates of DHHC5, I utilized an in vitro assay to test
DHHC5 enzymatic activity in the presence of recombinant protein substrates.
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Figure 7 Localization of DHHC5 in primary cardiomyocytes
(A) Immunofluorescence staining of neonatal rat ventricular myocytes (NRVM)
with anti-DHHC5. Golgi apparatus localization is indicated by arrows, and plasma
membrane localization is indicated by arrowheads. 71% of all NRVM cells (n=24
from 5 samples) showed plasma membrane localization as determined by
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blinded scoring. (B-E) Western blot analysis of NRVMs transfected with control
(Cont) and a mixture of two siRNAs targeting DHHC5 (KD). GAPDH is used as a
loading control. Same blot was stripped and re-probed with Calnexin, Gαs, and
Gαi to make sure there was no off-target effect on the proteins of interest. 20-40
µg of total proteins were loaded for the indicated lanes. The same siRNAs are
used to generate the data in Figure 8 of this chapter.
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Figure 8 DHHC5 is required for signaling downstream of β-adrenergic
receptor stimulation in cardiomyocytes
(A) Palmitoylation of Gαs, Gαi, and calnexin in control and DHHC5 knockdown
(KD) NRVMs treated with 10 µM isoproterenol (ISO) for indicated time points. (B)
Fold changes of palmitoylation levels of Gαs and Gαi normalized to calnexin at
the indicated time points compared to 0 min (n=3). (C) Quantification of cellular
cAMP levels before and after ISO (5 min) in control (black) and DHHC5
knockdown (red) NRVMs (n=3). (D) Quantification of beating frequency
monitored by Fura-2 before (baseline) and after ISO (+ISO) in control (black) and
knockdown (red) cells (n=5). *p<0.05; n.s. = not significant (paired t test). This
figure is modified from Chen, J. J., Marsden, A. N., Akimzhanov, A. M., &
Boehning, D. (2018) The palmitoyl acyltransferases DHHC5 mediates betaadrenergic signaling in the heart by targeting Gα proteins and G protein-coupled
receptor kinase 2. bioRxiv preprint. Copyrights for this article remain with the
authors.
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DHHC5 palmitoylates Gαs and Gαi in vitro
In collaboration with Dr. Marsden, I adopted a previously described in vitro
palmitoylation assay using a fluorescently labeled palmitoyl-CoA analog,
palmitoyl CoA{N-[(7-nitro-2-1,3- benzoxadiazol-4-yl)-methyl]amino} (NBD). It was
used to demonstrate that purified human DHHC20 and zebrafish DHHC15 can
robustly palmitoylate Legionella ubiquitin ligase GobX and human SNAP25B,
respectively [186]. We overexpressed FLAG-tagged human DHHC5 or the
catalytically inactive form DHHS5 in HEK293 cells, immunoprecipitated
DHHC/S5, and performed an on-bead enzymatic assay. To establish that the
NBD fluorescent signal is attached to the substrates via thioester bonds, we
added hydroxylamine to the reaction mix as a negative control (Figure 9). For
both no enzyme and catalytically inactive DHHS5 controls, we observed some
level of autoacylation of Gα proteins, which has been reported in previous studies
using [3H]Palmitoyl-CoA in vitro (Figure 10A,B; [222]). In the presence of
DHHC5, the rate of Gαs and Gαi palmitoylation was accelerated. In contrast, the
known palmitoylated protein GAPDH [223] showed no increased palmitoylation in
the presence of DHHC5 indicating substrate specificity (Figure 10C).
Additionally, an N-terminal mCherry-fused variant of DHHC5 performed similarly
to the FLAG-tagged variant validating that N-terminal tags do not appreciably
impact enzymatic activity or substrate recognition of this enzyme (Figure 11).
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Figure 9 Procedures of in vitro assay to identify direct substrates of DHHC5
First, flag-tagged DHHC5 or catalytically inactive DHHS5 were
immunoprecipitated (IP). The reaction was carried out on-bead with recombinant
substrate proteins and the Palm-CoA{N-[(7-nitro-2-1,3- benzoxadiazol-4-yl)methyl]amino} (NBD). Hydroxylamine (HA, red) was added as a negative control
to ensure the NBD signal detected is link to substrates via thioester bonds.
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Figure 10 Gαs and Gαi are direct substrates of DHHC5.
Palmitoylation of recombinant Gαs (A), Gαi (B), and GAPDH (C) in vitro with
mock IP (-), catalytically inactive form of DHHC5 (DHHS5), and DHHC5. As a
negative control, hydroxylamine (HA) is added to cleave palmitoylation. DHHC
total input as determined by Western blotting is shown below the palmitoylation
panels.
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Figure 11 mCherry-DHHC5 is catalytically active
(A-C) In vitro DHHC assay as in Figure 4 of the main text using mCherry-DHHC5
instead of FLAG-DHHC5. Palmitoylation of recombinant Gαs (A), Gαi (B), and
GAPDH (C) in vitro with mock IP (-), catalytically inactive form mCherry-DHHS5,
and mCherry-DHHC5. As a negative control, hydroxylamine (HA) is added to
cleave all thioester bonds.
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Discussion
Rapid, agonist-induce palmitoylation in signaling transduction
Palmitoylation is the only reversible lipid modification, and a growing list of
signaling proteins are known to undergo cycles of palmitoylation and
depalmitoylation [224, 225]. Recently, our group showed that the tyrosine kinase
Lck can be palmitoylated within a minute of Fas ligand stimulation in T cells,
suggesting that palmitoylation plays key role in rapid signal transduction
analogous to other post-translational modifications such as phosphorylation
[113]. Multiple members of the Gα protein family, including Gαs and Gαi, have
been shown to be palmitoylated in the N-terminus [170, 219]. In cell lines,
overexpression of Gαs and Gαi palmitoylation mutants showed defects in
membrane association [171, 226]. Stimulation of β-ARs in kidney fibroblast-like
COS cells and S49 lymphoma cells did not lead to detectable changes in Gα
protein palmitoylation levels using high performance liquid chromatography
(HPLC) [123], though an earlier study found that [3H]palmitate had increased
turnover after ISO stimulation [122]. One possible explanation is that
[3H]palmitate loading only labels a small fraction of the total Gα pool, which
cannot be detected using HPLC. Recent advances in palmitoylation detection
methods allow us to better study dynamic palmitoylation of endogenous Gα
proteins with endogenous lipids and their functional outcomes in specific cell
types. My data demonstrate extremely rapid palmitoylation kinetics of Gα
proteins following activation of the β-ARs and its temporal correlation with
downstream events in cardiomyocytes. The requirement of palmitoylation for β57

AR signaling were functionally demonstrated by transient knockdown of DHHC5,
which reduced or eliminated the majority of downstream effects of ISO
stimulation in cardiomyocytes.

DHHC5 is a novel regulator of cardiac functions
Few studies have examined the cellular function of DHHC5 and its link to
human diseases. One of the known substrates of DHHC5 is the neuronal
scaffolding protein PSD-95, which is enriched at the postsynaptic sites in
neurons [227]. Mice homozygous for a hypomorphic allele of Zdhhc5 gene
showed defects in learning and memory [227]. Curiously, PSD-95 palmitoylation
levels are not decreased in the hypomorphic mice, likely because PSD-95 can
also be palmitoylated by other DHHC enzymes in neurons [228]. Some of the
homozygous DHHC5 hypomorphic mice show lethality, suggesting its role in
early development [227]. Cardiomyocytes isolated from these mice showed
reduced massive endocytosis, a process that happens during re-oxygenation of
anoxic hearts [197]. Phospholemman and the cardiac Na/Ca exchanger were
identified as potential substrates of DHHC5 in regulating massive endocytosis
[197]. Several other studies on cardiac functions of DHHC5 also focus on its
substrate phospholemman in regulating sodium pumps in adult ventricular
myocytes [193, 194]. My data identify β-AR signaling, a pathway that is closely
associated with heart failure and is a major therapeutic target in cardiovascular
diseases, as a key target for the enzymatic action of DHHC5.
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Efficient detection of DHHC enzyme substrates in vitro
Several methods have been used to study palmitoylation of a specific
substrate by a DHHC enzyme of interest. For example, in the first study that
identified yeast transmembrane protein Akr1p to be a PAT, an in vitro assay was
used to showed that Akr1p can palmitoylate the type I casein kinase Yck2p [184].
This method utilized [3H]palmitoyl-CoA, purified Yck2p and Akr1p, in the
presence of ATP, MES, and bovine liver lipids [184]. Recently, a radiolabelingfree method was used to show that purified human DHHC20 and zebrafish
DHHC15 palmitoylate ubiquitin ligase GobX and SNAP25B, respectively [187]. A
dye conjugated to palmitoyl-CoA was used instead of [3H]palmitoyl-CoA. My
study modified this method further by performing an on-bead assay after
immunoprecipitating DHHC5, thus eliminating the necessity of having purified
DHHC enzymes. Additionally, my method showed substrate specificity because
DHHC5 did not palmitoylate GAPDH, a known palmitoylated protein.
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Chapter IV: The H9c2 cell line as an alternative to study protein
palmitoylation in β-AR pathways

Introduction
The H9c2 cell line is derived from BDIX rat ventricular heart tissue after
selective serial passages [229]. The original study described that H9c2 cells are
multinucleated, non-beating, spindle-shaped cells that show morphological,
biochemical, and electrophysiological features of muscle cells. Specifically,
electron microscopy revealed that the T-tubule structures of H9c2 cells were
more similar to those of skeletal muscle cells but not cardiac muscle cells [229].
One later study found that the majority of H9c2 cells are mononucleated, and did
not have gap junctions, caveolae, or T-tubules [230]. Further examination of the
electrophysiological properties revealed that after couple of weeks in culture,
H9c2 cells show inward voltage-dependent calcium currents similar to that of
cardiac muscle cells but not skeletal muscle cells. They also showed that H9c2
cells responded to isoproterenol stimulation and increased intracellular cAMP
[230]. Therefore, many studies focusing on cardiac signaling pathways have
since used H9c2 cells as a model. For example, one study found that H9c2 cells,
similar to NRVMs, display hypertrophic responses to both angiotensin II and
endothelin-1 [231].
Interestingly, H9c2 cells have 30% β1-AR and 70% β2-AR, a ratio that is
the opposite of that in rat heart tissue, but similar to that in human heart [232]. In
response to prolonged β-AR stimulation, β2-AR was down regulated both at the
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protein level and at the mRNA level [232], similar to the observation in NRVMs
that β2-ARs were reduced at the cell surface [233]. Despite the lack of caveolae
in H9c2 cells [230], one recent study showed that β1-AR and β2-AR are confined
to certain regions of the plasma membrane, and their interactions with anchoring
proteins are crucial for these localization patterns [234]. Given the similarities of
H9c2 cells with other cardiac cell models, I am interested in using it as an
alternative model to study DHHC5-mediated palmitoylation of Gα proteins. One
study showed that distinct classes of proteins can be palmitoylated in H9c2 cells
using [3H]palmitate labeling [235]. However, the identities of those proteins
remain uncharacterized. Additionally, the localizations and functions of DHHC
enzymes in H9c2 cells remain unknown.

Results
Activation of β-ARs does not induce rapid protein palmitoylation in H9c2
cells
Previous studies have shown that H9c2 cells are prone to further
differentiation when maintained in culture [236]. To verify that my culture of the
H9c2 cells still possess cardiac muscle properties, I stimulated the H9c2 cells
with endothelin-1 (ET-1), a peptide released by endothelial cells that stimulates
the ETA and the ETB receptors [237]. Previous study showed that H9c2 cells
expressed high level of ETA receptors and showed calcium release from the SR
storage in response to ET-1 stimulation, a process mediated by the RyRs [238]. I
used Fura-2 AM to monitor intracellular calcium level in live H9c2 cells. After
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stimulation with ET-1, in over 70% of the cells imaged we observed a calcium
transient (Figure 12A). Next, I want to study if there is stimulus-dependent rapid
palmitoylation of Gα proteins after ISO stimulation in H9c2 cells, like I observed
in NRVMs. I stimulated the cells with 10 µM ISO and performed ABE at the
indicated time points. I observed no change in palmitoylation levels of either Gαs
or Gαi proteins (Figure 12B). Downstream of the β-AR signaling pathway, I
found no significant change in cAMP levels after ISO stimulation (Figure 12C,D).
Additionally, there is no increase in intracellular calcium levels after ISO
stimulation (Figure 12E). These data suggested that despite the presence of the
β-AR signaling pathway, there is no rapid palmitoylation or inotropic responses to
ISO stimulation in H9c2 cells like those observed in NRVMs.
Next, I investigated if DHHC5 has similar localization patterns in H9c2
cells. Immunofluorescence staining showed that unlike in NRVMs, DHHC5 has
only Golgi/ER but no plasma membrane localization in H9c2 cells (Figure 13A).
These data combined suggested that H9c2 is not an ideal model for studying
rapid palmitoylation or more generally, contractile responses following β-AR
stimulation.
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Figure 12 Isoproterenol induces no increased palmitoylation of Gα proteins
in H9c2 cells
(A) Representative single cell trace of the Fura-2 ratio in a H9c2 cell treated with
1 µM endothelin-1 (ET-1) at the indicated time point. (B) H9c2 cells were treated
with 10 µM isoproterenol (ISO) for the indicated times. ABE was used to detect
palmitoylation levels. (C) Representative trace of H9c2 cells treated with 10 µM
ISO for indicated time points and intracellular cAMP concentration was measured
using ELISA. (D) Quantification of cellular cAMP levels before and after ISO
(2min) in H9c2 cells (n=3). (E) Representative single cell trace of the Fura-2 ratio
in a H9c2 cell treated with 10 µM ISO at the indicated time point.
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Figure 13 Localization of DHHC5 in H9c2 cells and NRVMs
Immunofluorescence staining of H9c2 cells (A) and neonatal rat ventricular
myocytes (B) with anti-DHHC5. Golgi apparatus localization is indicated by
arrows, and plasma membrane localization is indicated by arrowheads. (C)
Quantification of the percentage of cells with plasma membrane localize DHHC5
(n=5, * p<0.05, unpaired T test).
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Identifying potential cardiac protein palmitoylation sites in H9c2 cells
My ABE data showed that in h9C2 cells, GRK2 was palmitoylated with no
ISO stimulation (Figure 4A). Since there was no previous report on GRK2 being
a palmitoylated substrate, we used Acyl-PEG exchange (APE, Figure 14A)
assay [203] to find the number of potential palmitoylation sites on GRK2. APE
shares similar steps with ABE—free cysteine sites were first blocked using NEM,
followed by cleaving the palmitoylation site. Then a 5 kDa PEG was added to the
palmitoylation site and analyzed after Western blotting. Calnexin has two
palmitoylation sites [215] and was used as a positive control. I found that Gαs
and Gαi showed one single shift in molecular weight, consistent with previous
findings that Gαs and Gαi are palmitoylated at one single cysteine at the Nterminus (Figure 14B; [170]). I found that there was a single shift of GRK2
protein indicating that there is only one palmitoylation site (Figure 14B).
However, further mutagenesis study is still needed to identify the palmitoylation
site.

Discussion
In Chapter III we showed that in NRVMs, ISO stimulation leads to rapid
palmitoylation of Gα proteins by DHHC5. Despite previous studies reporting that
the β-ARs and their downstream signaling proteins are present in H9c2 cells, I do
not find similar rapid palmitoylation or downstream inotropic effects in my study.
Since I proposed that rapid palmitoylation of Gα proteins recruits them
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Figure 14 Identifying number of palmitoylation sites using Acyl-PEG
exchange assay
(A) Schematics of acyl-PEG exchange (APE) assay. The free cysteine sites are
blocked, followed by cleaving the thioester bond at the palmitoylation site, and
addition of a mass-tag of certain size. (B) APE assay using 5kD PEG on H9c2
cells. Calnexin was used as positive control. White arrowheads indicate nonpalmitoylated proteins. Black arrowheads indicate palmitoylated proteins. Grey
arrowheads indicate non-specific background signals that are equal in -HA and
+HA lanes (NS).
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into membrane subdomain caveolae for efficient signaling transduction, it is
possible that the lack of caveolae in H9c2 cells [230] lead to the absence of such
mechanisms. Additionally, I also found that endogenous DHHC5 is almost
exclusively localized to the Golgi/ER membrane, but not on the plasma
membrane in H9c2 cells. Though I cannot exclude the possibility that other
plasma membrane localized DHHC enzymes (DHHC20 or 21) may be able to
mediate rapid palmitoylation near the plasma membrane, it is clear that the
mechanisms of ISO-induced rapid signaling events are absent in H9c2 cells, and
therefore it is not a suitable model for studying stimulus-dependent palmitoylation
downstream of β-AR signaling.
Since GRK2 is palmitoylated without stimulation in H9c2 cells, I was able
to identify a single palmitoylation site on the protein. Previous studies have
shown that two other GRK family proteins, GRK4 and 6, are palmitoylated [178,
179]. GRK6 is palmitoylated at a cluster of cysteines near the C-terminal end at
position 561, 562, and 565 [178]. Based on an analogous alignment, GRK4 is
predicted to be palmitoylated at position 561 and 578 [179]. However, these sites
are not conserved in GRK2 and therefore further studies are required for
identifying the palmitoylation site(s).
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Chapter V DHHC5 is regulated by palmitoylation and
phosphorylation of the C-terminal tail

Introduction
DHHC5 has a ~500 amino acid (more than 70% total length of the protein)
C-terminal tail that is proposed to contain regulatory components that are crucial
for substrate recognition, localization, activation, and other potential functions
[194, 198, 199]. Truncation mutations of DHHC5 showed that the region between
amino acids 218 and 334 is necessary for recognizing substrates including
phospholemman and flotillin 2 [194]. In neurons, the tyrosine kinase Fyn
phosphorylates DHHC5 at Y533 and stabilizes it at the synapse by forming a
DHHC5/Fyn/PSD-95 protein complex [198]. In adult mouse forebrain extracts,
DHHC5 was found to be palmitoylated at three potential cysteines in the Cterminus tail, some of which are conserved in other DHHC enzymes [199]. One
recent study showed that DHHC6 is palmitoylated in the C-terminal tail by
DHHC16, revealing a novel palmitoylation cascade to fine-tune DHHC activities
[190]. However, the functional consequences of DHHC5 C-terminal tail
palmitoylation remain largely unknown.
Palmitoylation of various transmembrane proteins has been shown to
affect their localizations in membrane subdomains or their interaction with other
transmembrane proteins [64, 239-241]. To elucidate the potential functional
outcomes of DHHC5 palmitoylation specifically at the plasma membrane, we
need to exclude the population of DHHC5 proteins localized at the Golgi
apparatus membrane. Therefore, we utilized total internal reflection fluorescence
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(TIRF) microscopy to monitor fluorescently tagged DHHC5 proteins in live cells.
This technique is based on the theory of total internal reflection at the interface
between the coverslip (glass) and the sample (cells in media) when the light
source hits at a specific angle (critical angle) [242]. The reflection results in an
electromagnetic field generating the evanescent wave that excites only the
fluorophores close to the coverslip [243]. The thickness of the evanescent field is
dependent on the wavelength of the laser, illumination angle, and other factors
[242]. Some of the advantages of TIRF microscopy compared to traditional
epifluorescence microscopy include less photobleaching, little out-of-focus
fluorescence signals, and higher signal-to-noise ratio. TIRF microscopy,
sometimes combined with other techniques such as fluorescence resonance
energy transfer, has been used to monitor membrane protein properties including
their lateral mobility, clustering, and endocytosis in live cells [244-247]. In live
neonatal and adult ventricular myocytes, TIRF microscopy has been used to
monitor dynamic SR formation and rearrangements, ryanodine receptor
localization and clustering, and L-type calcium channel localization [248, 249].
Therefore, we believe that TIRF microscopy is useful in assessing the dynamic
localization of DHHC5 in NRVMs.
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Results
The C-terminal tail of DHHC5 is palmitoylated upon stimulation of β-ARs to
modulate downstream signaling in cardiomyocytes
DHHC5 contains a C-terminal tail that can be a target for post-translational
modifications to modulate enzyme structure/function (Figure 15) [250]. Three
potential palmitoylation sites in the C-terminal tail of DHHC5 have previously
been identified in mouse forebrain extracts (highlighted in Figure 15) [199]. In
order to determine if these sites are palmitoylated in NRVMs, I created single
mutants that changes Cys 236 or 245 to Ser, double mutant that changes both
Cys 236 and 245 to Ser, and removed all three potential palmitoylation sites by
deleting amino acids 236-245 (refer to as Δ236-245). DHHC enzymes are
autocatalytically modified at the active site with palmitate [185], and thus I
performed all ABE experiments using the catalytically dead mCherry-DHHS
constructs expressed in NRVM to only examine palmitoylation in the C-terminal
tail. I observed that the single mutants, the double mutant, and the deletion
mutant all showed no palmitoylation in the C-terminal tail (Figure 16A). These
data suggest that all three sites are palmitoylated and the absence of any one
site interferes with the palmitoylation at other sites. Next, Ie examined whether
the palmitoylation of the three Cys in the C-terminal tail changes after ISO
stimulation. I performed an ABE time course on the catalytically dead mCherryDHHS5 and mCherry-DHHSΔ236-245. I found that DHHS5 is palmitoylated
within one minute upon ISO stimulation, while this is lost in the DHHSΔ236-245
mutant (Figure 16B). This indicates that the C-terminal tail of DHHC5 is very
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rapidly palmitoylated in this cluster of Cys residues upon β-AR stimulation. To
address the functional outcomes of DHHC5 tail palmitoylation upon stimulation, I
knocked down DHHC5 in NRVMs and rescued downstream cAMP production
with both wild-type mCherry-DHHC5 and mCherry-DHHC5Δ236-245 (Figure
17A). I found that wild-type mCherry-DHHC5 restored cAMP production following
ISO stimulation, while mCherry-DHHC5Δ236-245 was incapable of rescuing
cAMP production (Figure 17B). Therefore, I conclude that palmitoylation of the
DHHC5 C-terminal tail is crucial for β-AR signaling. In collaboration with Dr.
Marsden and Dr. Scott, I next tested the hypothesis that DHHC5 palmitoylation in
the C-terminal tail leads to sequestration in membrane microdomains where it
can assemble with other components of the β-AR signaling pathway to facilitate
downstream signaling [149, 251, 252].
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Figure 15 Schematic of DHHC5 protein and the potential posttranslational
modifications in the C-terminal tail
Schematic of DHHC5 created by Protter [250]. The catalytic site DHHC is
highlighted in the green box. Three potential palmitoylation sites (236, 237, and
245) within the tail are enlarged and highlighted. Serine 376 and Serine 584, at
which truncation mutants have been made, are heighted (blue arrows).
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Figure 16 DHHC5 is palmitoylated at cysteines position 236, 237, and 245
after ISO stimulation
(A) ABE was used to detect palmitoylation of mCherry-DHHS5 wild-type (WT),
Cys 236 to Ser (C236S), Cys 245 to Ser (C245S) single mutants, Cys 236 & 245
to Ser double mutant (C236S C245S), and Cys 236 to Cys 245 deletion mutant
(Δ236-245) in NRVMs. (B) Palmitoylation of mCherry-DHHS5 and mCherryDHHS5Δ236-245 in NRVMs treated with 10 µM isoproterenol (ISO) for indicated
time points. Calnexin is used as positive control.
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Figure 17 Palmitoylation of the C-terminal tail of DHHC5 regulates signaling
in NRVM
(A) Western blot analysis of NRVMs transfected with control siRNA (Cont),
siRNA targeting DHHC5 (KD), siRNA targeting DHHC5 and wild-type mCherryDHHC5 (KD+WT), siRNA targeting DHHC5 and mCherry-DHHC5Δ236-245
(KD+Δ236-245). Endogenous DHHC5 and overexpressed mCherry-DHHC5 are
indicated by black and red arrowheads (left), respectively. GAPDH (black
arrowhead, right) is used as a loading control. (B) Quantification of cellular cAMP
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levels in control (black), knockdown (red), and knockdown and rescue with either
wild-type mCherry-DHHC5 (green) or mCherry-DHHC5Δ236-245 (blue) in
NRVMs. *p<0.05; N.S. = not significant (paired t test, n=3).
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Palmitoylation of the C-terminal tail of DHHC5 regulates stimulationdependent plasma membrane motility
To determine the effect of palmitoylation on DHHC5 membrane motility,
Dr. Marsden, Dr. Scott and I utilized total internal reflection fluorescence (TIRF)
microscopy [243]. We imaged live, beating NRVMs transfected with mCherryDHHC5 and mCherry-DHHC5Δ236-245. Both proteins were expressed in the
TIRF plane as laterally mobile puncta of various fluorescent intensities
presumably representing either single molecules or oligomers (Figure 18A-B)
[72, 253]. First, we confirmed that mCherry-DHHC5Δ236-245 can localize to the
plasma membrane appropriately like the wild-type proteins, with similar number
of observed particles in the TIRF plane (Figure 18C). We then examined the
lifetime of mCherry-DHHC5 particles in the TIRF plane to examine whether there
is stimulus-dependent removal or insertion of DHHC5 into the plasma
membrane. To accomplish this we used kernel density estimate analysis [254,
255] to calculate the lifetime of particles before and after 10 min of ISO
stimulation (Figure 18D-E). When comparing the particle distributions before and
after ISO stimulation, we observed a shift to longer lived particles after β-ARs
were activated (Figure 18D). In contrast, the mCherry-DHHC5Δ236-245 showed
the opposite result (Figure 18E). Thus, ISO stimulation led to the stabilization of
DHHC5 particles at the membrane, an effect that is lost in the palmitoylation
deficient DHHC5 mutant.
TIRF imaging has been widely used to examine lateral mobility of proteins
in response to receptor stimulation in multiple systems [256-258]. We next
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examined the lateral mobility of DHHC5 in the plasma membrane before and
after ISO stimulation. To quantify this, we calculated the mean squared
displacement (MSD) of all particles present before and after 10 min of ISO
stimulation. MSD calculates the summation of particle movement over time [259].
Stalling particles will show a straight horizontal line as a function of time, while
those moving quickly will show a steep slope. We found that the MSD of
mCherry-DHHC5 particles remains essentially unchanged before and after ISO
stimulation indicating no change in lateral mobility (Figure 18F). In contrast, the
mCherry-DHHC5Δ236-245 particles have an increase in the MSD after ISO
stimulation indicative of increased mobility (Figure 18G). In total, these data
indicate that DHHC5 is palmitoylated in the C-terminal tail after ISO stimulation
(Figure 16B), leading to stabilization in the plasma membrane (Figure 18D,F).
The DHHC5Δ236-245 mutant cannot be palmitoylated (Figure 16B), leading to
decreased lifetime at the membrane and increased motility (Figure 18E,G),
presumably reflecting increased ISO-stimulated removal from the TIRF plane.
Thus, palmitoylation of the DHHC5 C-terminal tail is critical for maintaining the
enzyme at the membrane after β-AR stimulation with potentially significant
consequences for palmitoylation-dependent signaling cascades.
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Figure 18 Palmitoylation of the C-terminal tail of DHHC5 regulates
stimulation-dependent plasma membrane motility
78

TIRF images of live NRVM transfected with mCherry-DHHC5 (A) and mCherryDHHC5Δ236-245 (B). (C) Average number of particles in the TIRF planes over
the 10 minute experiments for mCherry-DHHS5 (blue) and mCherryDHHC5Δ236-245 (orange). 95% confidence intervals are shown as
corresponding shaded areas and there is no difference because of the overlaps.
(D-E) Histogram with kernel density estimation (KDE) of the life-time of particles
at 0 (blue) and 10 min (orange) after isoproterenol (ISO) stimulation. (F-G) Meansquared displacement (MSD) shown in 30 second windows of particles that exist
continuously from 0 to 10 min of ISO stimulation. Each line represents one
particle. n=377 for mCherry-DHHC5 (D and F) and n=221 for mCherryDHHC5Δ236-245 (E and G).
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The C-terminal tail of DHHC5 is phosphorylated in response to stimulation
In addition to palmitoylation in the C-terminal tail, a previous study that
performed in vivo phosphoproteomics analysis in murine hearts also identified
multiple potential phosphorylation sites in DHHC5, including Ser at position 380,
425, 432, 554, and 636 [260]. Additionally, they observed that the
phosphorylation of Ser 636 is up regulated in response to β1AR stimulation,
potentially targeted by PKA [260]. Therefore, Dr. Marsden and I investigated
whether the C-terminal tail of DHHC5 is phosphorylated in NRVM after β-AR
stimulation. We used ISO and forskolin, a direct activator of ACs [261], and found
that endogenous DHHC5 proteins showed increased phosphorylation levels after
both stimulations (Figure 19A). The C-terminal tail of DHHC5 has 79 serine
residues. To narrow down the potential phosphorylation sites, we created
truncation mutants of mCherry-DHHC5 that change Ser 584 and 376 (highlighted
in Figure 15) to stop codons. Overexpression of the mutant proteins in NRVM
after ISO stimulation showed that DHHC5 is phosphorylated between position
376 and 583 (Figure 19B). There are 38 serines in between position 376 and
583. Therefore, further studies are still required to pinpoint the positions of
phosphorylated Ser site(s) on DHHC5, identify the kinase(s) and phosphatase(s)
that regulate its phosphorylation levels, and how phosphorylation affects DHHC5
activity in NRVM.
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Figure 19 DHHC5 is phosphorylated in response to β-AR stimulations
(A) Western blot analysis using phospho-serine specific antibodies (pSer) on
immuno-precipitated endogenous DHHC5 proteins from NRVMs stimulated with
10 µM forskolin or isoproterenol (Iso) for 5 minutes. (B) NRVMs are not
transfected (-) Control, or transfected with wild-type mCherry-DHHC5 (DHHC5),
truncated mCherry-DHHC5 where Ser 584 (584 Stop) or Ser 376 (376 Stop) is
mutated to a stop codon. After Iso stimulation, mCherry-DHHC5 proteins are
immunoprecipitated and analyzed using pSer antibodies. mCherry antibodies
were used to detect total protein levels.
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Discussion
Lipid subdomains and beta-adrenergic signal transduction in the heart
Lipid subdomains have been proposed to create signaling centers to
facilitate both signal propagation and inhibition. One of the lipid subdomains
present within many cell types is caveolae. Within cardiomyocytes, caveolae are
composed of caveolin-3, cholesterol, and sphingolipids. Caveolin proteins have
been proposed to create a scaffold, allowing signaling complexes to form at the
membrane. Multiple components of β-AR signaling have been identified in
caveolae, such as β2-AR, Gαs, AC5/6 and Gαi [149, 251, 252], indicating that
caveolae are central organizers of this pathway. DHHC5 itself has been shown to
be present in the caveolae, allowing for direct palmitoylation of phospholemman
[194]. Proteomic studies identified that palmitoylated proteins are predominantly
found in caveolae, suggesting that this is a better predictor of caveolae
localization than caveolin binding motifs [32]. My findings that DHHC5 is
palmitoylated in the C-terminal tail upon stimulation and this modification is
crucial for downstream cAMP production in cardiomyocytes implies that DHHC5
as well as its targets are likely enriched in caveolae to allow efficient signaling
transduction.
In cardiomyocytes, not much is known about DHHC enzyme regulation.
My findings highlight the central role of the C-terminal tail in modulating DHHC5
function in cardiomyocytes. In particular, we found that palmitoylation of the tail
had dramatic effects on plasma membrane retention after activation of the β-AR
pathway.
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DHHC5 phosphorylation and beta-adrenergic signaling
The tail region is highly variable in the DHHC family of enzymes, indicating
this region may be a central mediator of isoform-specific function and substrate
recognition. We identified that DHHC5 is phosphorylated at one or multiple
serine(s) between amino acids 376 and 583 in response to β-AR stimulation. Our
group found a positive feedback mechanism in T cells where Lck is palmitoylated
rapidly by plasma membrane localized DHHC21, which is activated by
downstream Ca2+ release [113]. Therefore, we hypothesize that a similar
mechanism may be present in cardiomyocytes where the phosphorylation of
DHHC5 is mediated by PKA, a kinase that is activated downstream of β-AR. My
results combined with a previous proteomic study [260] suggest that serines at
positions 380, 425, 432, and 554 are all likely phosphorylation sites. Future
studies will need to address how phosphorylation affects DHHC5 functions and
downstream signaling.
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Chapter VI Conclusion and Future Directions

β-AR signaling pathways are among the most well-studied pathways in the
heart under both physiological and pathological conditions. In this study, I
focused on the rapid changes mediating contractile functions after stimulation of
the β-ARs in primary cardiomyocytes. Though Gα proteins have been previously
identified as palmitoylated proteins with relatively fast turnover, relatively little is
known about how the rapid changes of endogenous palmitoylation levels impacts
cardiomyocytes physiology. In this study, I examined the functions of cardiac
DHHC5 and its direct targets Gα proteins in mediating ISO-induced changes in
contractility.

Distinctive palmitoylation profiles of β-AR signaling pathway in various
cardiac cells
The rat myoblast cell line H9c2 has been used in various studies that
examine the β-AR signaling pathways [231, 232]. Since β-ARs and downstream
proteins are expressed in H9c2 cells and there are reports of ISO-induced cAMP
production [230], I decided to use H9c2 cells as one of the models in my study
because they are easier to maintain and perform molecular studies when
compared to primary cardiomyocytes. The majority of my study is carried out in
neonatal rat ventricular myocytes (NRVMs) because there are well established
methods to monitor multiple downstream effects of β-AR signaling, including
cAMP production and rate of spontaneous beating [200]. Despite the wide use of
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NRVM as a model for studying β-AR signaling, it is often criticized for not being
as fitting a model for adult cardiomyocytes, especially in studies related to
pathological conditions such as heart failure. Therefore, at the beginning of my
study (Chapter III), I decided to identify the palmitoylated proteins in the β-AR
signaling pathways in all three cell types. I found that NRVM and adult rat
ventricular tissue shared similar palmitoylation protein targets, while H9c2 cells
showed GRK2 as an additional palmitoylated protein. Later I found that GRK2
can also be palmitoylated in NRVM, but only after ISO stimulation. My data
indicate that the kinetics of proteins palmitoylation vary between different cardiac
tissues, but the overall palmitoylated protein targets are similar among all three
cell types examined. It should be noted that the adult rat ventricular tissue
contains many cell types, of which myocytes comprise a minority. To fully
understand the roles of palmitoylation on signaling proteins downstream of β-ARs
in adult cardiomyocytes, future studies should be carried out in primary adult rat
ventricular myocytes (ARVMs).
The detected palmitoylated proteins in my study differ in some respects
from previous reports. For example, the PKA regulatory subunit is reported to be
palmitoylated in a proteomic study [217], but in my study I cannot conclusively
determine if it is palmitoylated given the relatively low level of signal compared to
the negative control. Additionally, I was also not able to detect AC6
palmitoylation, which was reported in another proteomic study [218]. This may be
due to the limitations of ABE as my detection method. Future studies using other
methods including Acyl-RAC or metabolic labeling can be helpful in confirming
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whether PKA regulatory subunit and AC6 are indeed palmitoylated in cardiac
cells. Another class of known palmitoylated proteins [165, 166] that I did not
examine are β-ARs because they cannot be reliably detected using the ABE
experimental settings as described in Chapter III. As an important technical
consideration, I have found that the detection of palmitoylated proteins using
ABE method is dependent on the type of detergent used to extract the proteins.
For transmembrane proteins (such as DHHC5 in Chapter V), I found that DDM
could not extract most of the transmembrane proteins and instead I used sodium
dodecyl sulfate to lyse the cells before ABE.
The differences of protein palmitoylation between NRVM and H9c2 cells
were more evident when we examine the rapid, stimulus-dependent
palmitoylation of Gαs and Gαi. In Chapter IV, I concluded that H9c2 cells
showed no significant changes in palmitoylation levels of both Gα proteins as
well as downstream cAMP production or intracellular calcium levels. This could
be partially explained by the lack of plasma membrane localized DHHC5 in H9c2
cells. There are three DHHC enzymes that were previously demonstrated to be
localized at the plasma membrane: DHHC5, 20, and 21 [70]. DHHC enzymes
have some level of substrate redundancy [71, 262] and therefore I cannot rule
out the presence of other DHHC enzymes in H9c2 cells that palmitoylate proteins
at the plasma membrane. Future studies are needed to identify the expression
and localization of these DHHC enzymes in various cardiac cells. Therefore, I
conclude that H9c2 cells are not suitable model for studying dynamic
palmitoylation of signaling proteins downstream of β-ARs. However, H9c2 can
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still be useful for some preliminary studies, including identifying the palmitoylation
sites of proteins of interest.

Stimulus-dependent palmitoylation and β-AR signaling in cardiomyocytes
Protein palmitoylation is a common post-translational modification and the
only reversible lipid modification. Proteomic studies suggested that at least 10%
of the proteins encoded by the human genome are palmitoylated [188]. Protein
palmitoylation results in various functional outcomes, including enhancing protein
affinity to the membrane, shuttling proteins between different cellular membrane
compartments, recruiting proteins to submembrane domains, regulating protein
stability and protein-protein interaction (reviewed in [263, 264]). As mentioned in
Chapter I, the recent development of non-radiolabeling methods to detect protein
palmitoylation largely enhanced the understanding of dynamic protein
palmitoylation and their roles in specific signaling pathways. Our group was one
of the first to show that palmitoylation can occur with extremely rapid kinetics
(within one minute) after extracellular stimulation, which recruits the palmitoylated
proteins into lipid rafts to form a macromolecular complex that facilitate
downstream signaling transduction [113]. In this study, I found a similar
mechanism for β-AR signaling pathways in primary cardiomyocytes.
In Chapter III, I examined the changes in palmitoylation levels of
endogenous proteins in primary cardiomyocytes stimulated by isoproterenol. I
found a temporal correlation between the kinetics of Gαs and Gαi palmitoylation
and downstream cAMP production and inotropic effects. After GPCR activation,
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Gα proteins dissociate from the receptor and the Gβγ subunits [204]. I concluded
that both Gαs and Gαi palmitoylation enhanced their localization to membrane
subdomain caveolae, where the downstream effector adenylyl cyclase almost
exclusively resides [149]. Gαs and Gαi have opposite effects on adenylyl
cyclase. Under physiological conditions, the majority of the β-ARs in
cardiomyocytes are coupled to Gαs. Therefore, I conclude that palmitoylation did
not show any preference between Gαs and Gαi, but the abundance of functional
Gαs leads to an overall positive inotropic effects. In this study, isoproterenol
activates both Gαs-associated β1AR and β2AR, which can couple to both Gαs
and Gαi [133]. Previous studies showed that β1AR localizes throughout plasma
membrane while β2AR is enriched in caveolae [149]. Future studies using
subtype-specific agonists are required to decipher whether stimulation of β1AR or
β2AR leads to distinctive downstream palmitoylation level changes.
A previous study has identified a single palmitoylation site on both Gαs
and Gαi at Cys position 3 [170]. Mutation studies in cell lines showed that
palmitoylation of Gαs and Gαi are essential for their membrane association and
interaction with various RGS proteins [171, 172]. My study in primary
cardiomyocytes showed only a temporal correlation between palmitoylation and
downstream inotropic effects. Based on a previous study using membrane
fractionation, palmitoylated Gαi proteins are shown to be enriched in lipid raft-like
low-density membranes [265]. Therefore I conclude that palmitoylation of Gα
proteins in cardiomyocytes leads to their localization to caveolae. Though my
results from the DHHC5 knockdown cells proved the importance of palmitoylation
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in β-AR signaling, future studies using the Cys 3 mutants of Gα proteins are
needed. Since I concluded in Chapter IV that H9c2 cells are not a fitting model to
study agonist-induced palmitoylation, we propose that mutating the endogenous
Gα proteins using the CRISPR-Cas9 system in beating myocytes such as the
human stem cell derived cardiomyocytes (method established in [266]) would be
a useful model.
My study also identified GRK2 as a novel palmitoylation target. Other
members of the GRK protein family, including GRK4 [179] and GRK6 [178], have
been shown to have multiple palmitoylation sites. However, in Chapter IV I
showed that GRK2 likely has only one palmitoylation site. Interestingly, I only
observe palmitoylated GRK2 after ISO stimulation in NRVM. The kinetics of
GRK2 palmitoylation is slower than that of Gα proteins, suggesting that the
negative feedback of the β-AR signaling occurs at later time points. A previous
study in adult rat ventricular myocytes showed that after 5 minutes of ISO
stimulation, GRK2 showed plasma membrane translocation [267]. This timeline is
consistent with my observation of the increase in palmitoylation level of GRK2.
Previous studies also suggested that GRK2 localization to the plasma membrane
is dependent on its binding to the Gβγ subunits [162, 163]. Future work is needed
to reveal the functional outcomes of GRK2 palmitoylation.
My findings in Chapter III also showed that the palmitoylation levels of
Gαs and Gαi went down while that of GRK2 remains the same after 30 minutes
of stimulation. These findings suggest that there are enzymatic regulators that
actively remove the palmitate moiety on both Gαs and Gαi. There are two well-
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characterized acyl protein thioesterases (APT1/2) that are responsible for the
removal of palmitate from proteins [74-77]. Additionally, the α/β-hydrolase fold
(ABHD) family of serine hydrolases was identified as novel depalmitoylating
enzymes [79, 80]. APT1 has been shown to remove palmitoylation groups on
Gαs and Gαi in vitro [76]. However, further study on the expression of APT
proteins and ABHD proteins are required to characterize their potential cardiac
functions and to identify which proteins are responsible for the agonist-induced
depalmitoylation of Gα proteins.

DHHC5 is a novel regulator of Gα palmitoylation and β-AR signaling in
cardiomyocytes
In Chapter III, I established that DHHC5 directly palmitoylates Gαs and
Gαi proteins and is crucial for signaling transduction downstream of β-ARs. A
previous study showed that the Golgi-localized DHHC3 and 7 palmitoylates
multiple Gα proteins [214]. In their study, Tsutsumi et al. first screened all 23
mammalian DHHC enzymes by overexpressing each one of them with tagged
Gαq, Gαs, or Gαi2 in HEK 293T cell and then observed whether there is
increased incorporation of [3H]palmitate. Overexpression of DHHC3 and 7
enhanced palmitoylation of all three Gα proteins, and Gαi can also be
palmitoylated by DHHC2 and 21. However, Tsutsumi et al. focused only on Gαq
as the palmitoylated substrate in their knockdown study and in vitro
palmitoylation assay. Therefore, they cannot conclusively rule out the possibility
that other DHHC enzymes can efficiently palmitoylate Gαs and Gαi.
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A recent study showed that one DHHC enzyme can trans-palmitoylate
another DHHC protein and alter its activity [190]. Therefore, overexpression of
DHHC proteins in cells lines is not an ideal method to study their direct activities
on substrates. My study is the first to show that Gαs and Gαi are direct
substrates of DHHC5 through an in vitro palmitoylation assay. Most of the
previous in vitro palmitoylation assays used [3H]palmitoyl-CoA [124] or require
purified DHHC proteins [186], I used a palmitoyl-CoA derivative conjugated to a
dye for easy visualization of the palmitoylation signal and we used
immunoprecipitated DHHC enzymes. I confirmed that the conjugated palmitoylCoA is added to the substrate via thioester bond. Additionally, I provided
evidence that DHHC5 has substrate specificity in my assay conditions. My
results do not exclude the possibility that other DHHC enzymes can palmitoylate
Gαs and Gαi. It would be interesting to test whether other DHHC enzymes,
especially the plasma membrane localized DHHC20 and 21, are able to
palmitoylate Gα proteins. Another limitation of my method is that there can be
other proteins, including activators or inhibitors of DHHC5, co-precipitating with
DHHC5 in my in vitro assay. To exclude the potential influences by coprecipitated proteins, future studies using purified DHHC5 proteins are still
needed.
In addition to palmitoylation, Gαi proteins are also myristoylated at the Nterminus [268]. Some studies suggested that N-myristoylation is required for
subsequent palmitoylation [269, 270]. Other studies suggested that the
palmitoylation status of Gαi is not dependent on myristoylation [271]. My in vitro

91

palmitoylation assay results using non-myristoylated recombinant Gαi proteins
supported the latter theory. However, given that my assay is performed without
the presence of any membrane systems, I cannot conclusively show that the
myristoylation and palmitoylation are two independent events in vivo.
In Chapter III, I showed for the first time that DHHC5 is required for the
signaling events downstream of β-AR stimulation in primary cardiomyocytes. As
discussed in Chapter I, previous studies on the cardiac functions of DHHC5
focused largely on its substrate phospholemman and the subsequent massive
endocytosis process. The existing DHHC5 hypomorphic mouse model shows
severe cardiac developmental defects [227] and therefore may not be suitable for
studying β-AR signaling mediated inotropic responses in physiological and
pathological conditions.
A previous study in human patients with heart failure showed that
decrease β-adrenergic responses to catecholamine is a major contributor to the
disease [272]. It has been proposed that restoring the β-AR signaling responses
is beneficial. For example, transgenic mice overexpressing β2AR in heart showed
improved cardiac contractility [273]. However, prolonged activation of the β-AR
signaling pathway is deleterious and leads to the activation of GRK-mediated
receptor internalization (reviewed in [274]). Transgenic mice overexpressing Gαs
showed enhanced left ventricular functions at early stages and severe
cardiomyopathy as they age [275]. Therefore, cardiac specific and inducible
DHHC5 deficient or overexpression transgenic animal models will be useful to
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understand the mechanism through which DHHC5 regulates β-AR signaling in
vivo.

Palmitoylation of DHHC5 in the tail region regulates its function
In Chapter V, I reported that DHHC5 is palmitoylated at three Cys sites in
the C-terminal tail. Mutation of one of the three sites is sufficient to abolish
palmitoylation at all three sites. For many of the proteins with multiple
palmitoylation sites including calnexin and β2AR, mutating one cysteine is not
sufficient to abolish palmitoylation on the other site(s) [168, 216]. In the case of
calnexin where the palmitoylation sites are adjacent (Cys 502 and 503), the
majority of calnexin proteins are either non-palmitoylated or dual-palmitoylated,
and mutating either site is sufficient to change protein functions [215]. My data
suggest a similar all or none model for DHHC5 tail palmitoylation.
My study is the first to show that there is stimulus-dependent dynamic
palmitoylation in the DHHC5 tail. The kinetics of DHHC5 palmitoylation are
similar to that of Gαs and Gαi, supporting my model that palmitoylation promotes
the spatial proximity of signaling proteins at the plasma membrane to facilitate
efficient signaling transduction. However, to confirm whether palmitoylation
promotes the interaction between DHHC5 and Gα proteins, or whether
palmitoylation promotes DHHC5 localization into caveolae, future studies using
dual-color TIRF microscopy or other complementary techniques are required.
It is clear from my TIRF microscopy data that palmitoylation stabilizes
DHHC5 proteins at the plasma membrane after ISO stimulation in NRVMs. TIRF
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microscopy has been used to study transmembrane protein dynamics after
cellular stimulation in other studies [256-258]. For example, one study using
Chinese hamster ovary (CHO) cells showed that γ-aminobutyric acid (GABAB)
receptors showed increased lateral mobility after agonist stimulation, while β-ARs
showed no such changes [257]. However, few studies have linked dynamic
changes observed at the plasma membrane using TIRF microscopy with
downstream signaling events. In Chapter V I showed that DHHC5Δ236-245
mutant failed to rescue downstream cAMP production in DHHC5 knockdown
cardiomyocytes. My data suggested that stabilization of DHHC5 at the plasma
membrane by palmitoylation of the three Cys in the tail region is necessary for βAR signaling. Since there are endogenous DHHC5 proteins present when I
examine recombinant DHHC5 tail palmitoylation, I cannot conclude whether
DHHC5 trans-palmitoylates or is regulated by another DHHC enzyme.

General conclusions and significance
Defects in β-AR signaling contribute to the pathogenesis of heart failure
[276, 277]. Therefore, understanding the regulatory mechanisms of β-AR
signaling is crucial for therapeutic intervention. S-palmitoylation is a reversible
post-translational modification that plays an important role in regulating protein
localization, trafficking, and stability. Multiple groups have studied the dynamic
palmitoylation of Gα proteins in cell lines and in vitro models [120-122]. However,
my study is the first to show that activation of β-ARs in cardiomyocytes leads to
rapid DHHC5-mediated palmitoylation of Gα proteins to regulate contractile
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functions (Figure 20). Mystudy also suggested that DHHC5 is an important
mediator of myocytes contraction and a potential drug target under pathological
conditions.
To date, there is no report of specific inhibitor for DHHC5 or any other
single DHHC enzyme. The most commonly used inhibitor for palmitoylation is 2bromopalmitate (2-BP). 2BP is a palmitate analog that irreversibly inhibits
multiple cellular processes including lipid metabolism [278] and S-palmitoylation
[279]. Interestingly, it is reported that 2-BP also inhibits the depalmitoylating
enzyme APT1 [169]. By using a click-inducible 2-BP analog, one study found that
it does not preferentially target DHHC enzymes [280]. These studies indicate that
2-BP is not an ideal inhibitor for protein palmitoylation. One recent study found a
new class of compounds based on a bis-cyclic piperazine scaffold to be efficient
and specific inhibitors for yeast Erf2 (homolog of the mammalian enzyme
DHHC9). In the past decade, there has been growing interest in studying the
reaction mechanisms of DHHC enzymes and the underlying structural biology
[186], both of which are critical for the development of drugs targeting these
proteins. Due to the potential involvement of these enzymes in a wide variety of
pathological conditions such as cancer, cardiovascular, and neurological
diseases, I believe that the development of inhibitors targeting specific
mammalian DHHC enzymes is an important goal for improving human health.
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Figure 20 Model of DHHC5-mediated palmitoylation of Gα proteins in
cardiomyocytes
Agonist stimulation of beta-adrenergic receptors (β-ARs) leads to palmitoylation
(red lines) of Gα proteins and their recruitment into caveolae (grey) where they
activate adenylyl cyclase (AC). Subsequently cAMP is produced and protein
kinase A (PKA) is activated. PKA phosphorylates downstream substrates and
leads to positive inotropy. DHHC5 is palmitoylated at three sites in the C-terminal
tail. It is also phosphorylated at one (or multiple) serine(s) between amino acid
376 and 583. Extra=extracellular; Intra=intracellular; P=phosphorylation
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Future perspectives of palmitoylation and its enzymatic regulations
Protein palmitoylation is one of the most crucial post-translational
modifications that regulate a wide variety of cellular processes in all cell types.
Recent advances in techniques enable the discoveries of novel palmitoylated
proteins and their palmitoylated Cys sites using proteomic approaches [109, 110,
112, 281]. The functional outcomes of protein palmitoylation include anchoring
cytosolic proteins to the plasma membrane, targeting proteins to membrane
subdomains, regulating protein stability and interactions. My study and other ongoing projects from our lab aim to understand how palmitoylation of signaling
proteins is regulated and how protein palmitoylation spatially and temporally
coordinates with downstream events in specific cell types. Here are some of the
major questions in the field of palmitoylation and its enzymatic regulations that
remain to be addressed in the near future.
What is the physiological relevance of protein palmitoylation? With recent
advances in genomic editing, building various tissue-specific animal models will
be helpful in understanding the functional importance of palmitoylation. Multiple
approaches, including mutating the palmitoylated Cys residues on target proteins
and knocking out one (or multiple due to potential functional redundancy) of the
DHHC enzymes, are needed to study the physiological processes regulated by
protein palmitoylation.
Is palmitoylation of specific subsets of proteins disrupted or enhanced in
various diseases? Studies using well-established in vivo animal models, such as
surgical, toxin-induced, or genetic models for heart failure, as well as human
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patient samples are needed to determine how palmitoylation is regulated
differently compared to normal conditions.
How does palmitoylation potentially affect other posttranslational
modifications on target proteins? Many palmitoylated proteins, including Gα and
DHHC5 in my study, undergo other types of lipidation or phosphorylation.
However, the level of cross-talk and the regulatory mechanisms between
palmitoylation and other modifications remain largely unsolved.
How are depalmitoylation enzymes regulated? Compared to the amount of
studies on DHHC enzymes, the understanding of depalmitoylating enzymes
APTs and ABHD proteins is still rudimentary. Future studies need to focus on the
substrate specificity and spatiotemporal regulations of depalmitoylation enzymes.
My project is one of the first that studies dynamic palmitoylation of target
proteins by a specific DHHC enzyme in cardiomyocytes. Some of the techniques
developed in my study will be useful for future investigations of cellular functions
of protein palmitoylation. As listed in this chapter, there are still many questions
remain to be answered regarding the molecular, cellular, and physiological
functions of protein palmitoylation.
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